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ABSTRACT
I n this study,. the neuroblastoma x glioma cells NG108-15
were used to investigate the effects of unsaturated fatty acids
3 2
on opiate receptor binding characteristics. Binding of H-D-ala-
5
D-leu -enkephalin to intact cells or cell membrane preparations
was significantly reduced when cells were cultured in lipid-free
medium supplemented with unsaturated fatty acid. The degree of
opioid binding reduction appears to correlate with the degree of
unsaturation of fatty acids. The effect of unsaturated fatty acid
on opioid binding reduction follows a slow time course in a dose
dependent manner. Scatchard analysis shows that there is a
proportional decrease in binding capacity with little change in
binding affinity when cells were grown in medium containing fatty
acid of increasing unsaturation. This decrease in opioid binding
is reversible and the restoration of binding activity can be
blocked by protein synthesis inhibitor, indicating that re-
synthesis of receptor protein is required. On the other hand, the
effect of unsaturated fatty acids on opioid binding is unlikely
to be linked with the level of endogeneous opioid-like compounds
synthesized by the cells.
Parallel studies of adrenergic receptor binding when cells
were grown in medium supplemented with unsaturated fatty acids
3
give opposite results. H-para-aminoclonidine binding to intact
cells or membrane preparations increases when cells were grown in
the presence of unsaturation fatty acids. On the other hand,
unsaturated fatty acids exposure to cells do not produce
significant changes in Na/ K -ATPase activities as well as
enkephalin-degradative enzyme(s) activities. The results of these
parallel studies suggest that the effect of unsaturated fatty
acid on opioid binding reduction is rather specific. The most
probable mechanism to account for this effect may be related to
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I.1 Historical aspects of the discovery of opiate receptor
Opiates are a group of drug originally derived from the
juice of the opium poppy that have predominant analgesic action.
Among them, morphine is the most well-known because of its
addictive nature that creates serious social problems. The
search for a non-addictive potent opiate was thus the underlying
motivation in opiate research.
It was suspected that there are specific opiate binding
sites in the central nervous system (CNS). This idea is
supported by the fact that some opiates derivatives are extremely
more potent than morphine and that only the levo form of the
isomer is active. The presence of structurally related drugs that
act as antagonists, like naloxone, also lend support to the idea
that specific binding sites are involved in opiate actions.
The presence of opiate receptors in mammalian tissue was
first demonstrated by Goldstein et al. in 1971. They found that
opiates can stereospecifically bind to mouse brain membranes
homogenates and proposed that there exsist specific binding sites
fo-r opiates. Two years later, Pert and Synder (1973), Simon et
al. (1973) and Terenius (1973) independently identified the
2binding of radioactively labelled opiates to brain tissue that
were highly stereospecific. These binding sites were later shown
to be the pharmacological relevent sites since the binding
affinities of the drugs are closely related to their analgesic
potencies.
During the past decade, great progress has been made in our
understanding of the opiate receptors at the molecular level. The
discovery of endogeneous opioid peptides has further expended'
this field into a new era.
1.2 Endog eneous opioid peptides
The endogeneous opioid peptides can now be refered to a
group of naturally occurring peptides that has a wide spectrum of
opioid like properties such as analgesia. The research on the
opioid peptides is a rapid developing and exciting area. In the
past decade, an enormous amount of information have accumulated
and that it is difficult to make a comprehensive description in
this field of research. In this section, I intend to outline
some of the important findings in the classification,
distribution and possible physiological functions of the opioid
peptides.
Overview of the discoveries of endogeneous opioid peptides
After the discovery of specific binding sites of opiates in
3mammalian brain tissue, elegant research efforts have been
carried out to search for the naturally occurring ligand for the
opiate binding sites. This came from the belief that the animals
tissue would not synthesize these specific sites just for the
binding of exogeneous opiates derived from plants.
Evidence for the presence of endogeneous opiate ligands in
the brain was first reported by Hughes et al. in 1975. They
isolated and purified two penta-peptides, namely, the methionine-
enkephalin and leucine-enkephalin that have opiate-like activity
in both bioassay and binding assay. The two peptides have the
similar structures with only one different amino acid residue at
the C-terminal. The structures of met-enkephalin and leu-
enkephalin are Try-Gly-Gly-Phe-Met and Tyr-Gly-Gly-Phe-Leu
respectively.
One year later, another opioid peptide which is now called
B-endorphin was isolated and characterized (Li & Chung, 1976
Bradbury et al., 1976). It is a 31 amino acid peptide
corresponding to a portion of the pituitary hormone B-lipotropin
that has the potent opiate-like activity both in vitro and in
vivo. In addition, B-endorphin contains the sequence of met-
enkephalin at the N-terminal. Subsequently, other B-endorphin
related peptides such as gamma-endorphin and alpha-endorphin were
also isolated and characterized (Gui llemin et al., 1976 Ling et
al., 1976; Verhoef et al., 1980).
In 1979, Goldstein et al. (1979,1981) reported the isolation
4of a leu-enkephalin containing peptide from porcine pituitary and
that this peptide has extraordinary high potency in the guinea
pig ileum assay. Because of this, the peptide is called
dynorphin. It is a basic opioid peptide containing Lys and Arg
residues at the C-terminal.
Other opioid peptides that lend not much attention. were also
isolated from other laboratories (Ueda et al., 1980; Henschen et
al., 1979; Brautl et al., 1981; Chang et al., 1981; Montecucchi
et al., 1981).
B. Families of opioid peptides
With the aid of modern techniques in molecular biology, it
has become quite clear that the opioid peptides can be classified
into at least three families, depending on their biosynthetic
origins. They are the pro-opiomelanocortin family, pro-enkephalin
A family and the pro-enkephalin B family. All the opioid
peptides being isolated so far belong to one of these three
peptides families that share a common precursor molecule. Pro-
opiomelanocortin is the common precursor for B-endorphin and ACTH
(Herbert, 1981); pro-enkephalin A is the common precursor
molecule for met-enkephalin and leu-enkephalin, as well as
several other opioid peptides originally isolated from bovine
adrenal medulla (Kilpatrick et al., 1982); pro-enkephalin B, on
the other hand, is the common precursor molecule for leu-
enkephalin, dynorphin and its related peptides (Kakidani et al.,
1982).
1. Pro-opiomelanocortin family: It has long been observed that
there was a link between B-lipotropin (B-LPH), B-endorphin and
ACTH (Guillemin et al., 1977). Mains et al. (1977) and Roberts
Herbert (1977) used protein chemistry and cell-free translation
method to demonstrate the existence of a precursor molecule
common to B-endorphin, B-LPH, ACTH, a-melanocortin(a-MSH), r-MSH
and corticotropin-like intermediate lobe peptide (CLIP), which is
now known as the pro-opiomelanocortin (POMC). It is a 31 K
dalton glycoprotein with sugars attached to its N-terminal. The
processing of POMC appears to be tissue specific. In the
anterior pituitary, it is processed from 31 K to B-LPH and 20 K
ACTH B-LPH is further cleaved into B-endorphin and r-LPH, and
20 K ACTH into 13 K ACTH and finally into 4.5 K ACTH. On the
other hand, in the intermediate lobe of pituitary, POMC is
processed slightly different from that in anterior lobe. ACTH is
cleaved into a-MSH and CLIP and B-endorphin is further cleaved
into B-endorphin 1-27 or B-endorphin 1-26. These endorphins are
then a-N-acetylated which inactivate their opiate-like
properties. In the brain tissue, the processing of POMC is
believed to resemble that of the intermediate lobe.
2. Pro- enkephalin A family: Early work on the biosynthesis of
enkephalins have shown that the adrenal glands of some species
are particularily rich sources of enkephalins and enkephalin-
containing peptides (Mizuno et al., 1980a, b Lewis et al., 1980
Kilpatrick et al., 1981). Later, a larger molecule that contains
6the sequence of enkephalins and related peptides was also
isolated from the adrenal chromaffin cells of some species
(Kilpatrick et al., 1982). By recombinant DNA techniques, the
complete sequence of this precursor molecule was elucidated (Comb
et al., 1982 Gubler et al., 1982 Noda et al., 1982). The
precursor molecular, now called pro-enkephalin A, contains six
molecules of met-enkephalin and one molecule of leu-enkephalin.
However, depending on how enzymatic cleavage is processed, it
also produces some C-terminally extended met-enkephalin
sequences viz, met-enkephalin-Arg-Gly-Leu and met-enkephalin-
Arg-Phe. Another peptide, called peptide E, which contains both
met-enkephin at N-terminal and leu-enkephalin at C-terminal was
isolated from adrenal extract and was shown to have potent
opiate-like activtiy (Kilpatrick et al., 1981). Smaller fragments
of peptide E have also been detected in adrenal extract,
including BAM-22 P, BAM 20-P AND BAM-12 P (Mizuno et al.,
1980a,b Kalpatrick.et al., 1981). However, up to the present
stage, it is unclear as to what are the major products of pro-
enkephalin cleavage.
3. pro-enkephalin B (prodynorphin) family: The apparent lack of
dynorphin-related sequence in pro-enkephalin A has provoked the
active search for a common precusor for dynorphin and its related
peptides. Two years ago, this peptide precursor was identified
from porcine hypothalamus that encodes the complete sequence of
dynorphin and a-neo-endorphin. It contains no met-enkephalin
sequences and is now called pro-enkephalin B or prodynorphin
7(Kakidani et al., 1982). It is a 256 amino acids peptide that
contains three copies of leu-enkephalin, two of which represent
the N-terminal of a-neo-endorphin and dydorphin.
The POMC, pro-enkephalin A and pro-enkephalin B (prod ynor-
phin) systems thus provide a pretty model to account for the
origin of all known opioid peptides. Fig. 1.1 shows the
schematic diagram of these three families of opioid peptides
(after Hol lt, 1983). All the three precursors have molecular
weights in the region of 28-32 K daltons and contain repeative
sequences. POMC, for example, contains three MSH sequences pro-
enkephalin A contains six copies of met-enkephain and 1 copy of
leu-enkephalin while prodynorphin contains three copies of leu-
enkephalin.
C. Distribution of opioid peptides
With the techniques of radioimmunoassay and immunohistochem-
istry, workers in this field were able to localize and quantitate
the opioid peptides throughout the mammalian central nervous
system as well as some peripheral tissues. It was evident that
the distribution patterns of the three families of opioid
peptides are also significantly different.
1. POMC family: B-endorphin was found in high concentrations in
both the anterior and intermediate lobes of pituitary (Rossier et
al., 1977 Fratta et al., 1979). In addition, B-endorhin has
also been detected in peripheral tissues such as the pancreas
Fig. 1.1 Schematic representation of bovine pre-opiomelanocortin,
bovine pre-pro-enkephalin A and porcine pre-pro-
enkephalin B( Hollt, 1983).
8(Bruni et al., 1979), the antrum (Feurle et al., 1980 Tanaki et
al., 1982) and the placenta (Liotta et al., 1982) indicating the
diversified physiological action of B-endorphin.
I n the brain tissue, B-endorphin and its related peptides
have been identified in the hypothalamus, mid-brain, amygdala,
dorsal colliculi and brain stem. In contrast, no B-endorphin
activity was detected in the cerebellum, the cortex and the
corpus striatum (Bloom et al., 1978 Zakarian Smyth, 1979).
The hypothalamus was the major site of B-endorphin in the brain.
Evidence has been obtained showing that brain B-endorphin is not
derived from that of the pituitary (Bossier et al., 1979).
2. Pro-enekphalin A family: Enkephalins, on the other hand, are
widely distributed in the CNS parellel to that of opiate receptor
distribution (Yang et al., 1977 Lindberg et al.,1979). The
concentration of met-enkephalin, on the whole, is about four
times higher than leu-enkephalin. This is agreeable with the
structure of pro-enkephalin A which has 6 copies of met-
enkephalin for every copy of leu-enkephalin. There might also be
some overlapping in the processing of pro-enkephalin A and
prodynorphin as revealed by the regional variation of met-
enkephalin to leu-enkephalin ratio (Weber et al., 1982).
Apart from the brain tissue, opioid peptides belonging to
the pro-enkephalin A family have also been detected with the
highest amount in the bovine adrenal medulla, which contains very
9little prod ynorphin-derived peptides.
3. Pro-dynorphin family: The dynorphin and its related peptides
were found with high concentration in the hypothalamic-posterior
pituitary axis (Cox et al., 1982) and hypothalamus (Goldstein
Ghazarossian, 1980). It is also interesting to find that
dynorphin co-exsists with vasopressin in the magnocellular
neurons of the posterior pituitary (Watson Akil, 1982).
D. Physiological functions of opioid peptides
Although a lot of research efforts have been devoted to this
area, the exact physiological roles of opioid peptides are still
by- and-large unknown. Interest of the opioid peptides has been
focused on the sensory, respiratory, circulatory and
neuroendocrinolgical systems. The clinical perspectives of
opioid peptides in mental diseases and pathological states are
also of great concern. In this section, some of the possible
physiological properties of opiate peptides will be presented:
1. Candidates of neurotransmitters or neuromodulators: The
enkephalins have been shown to meet many criteria for neurotrans-
mitters (Synder, 1980). Neurotransmitters refer to substances
released from neuronal terminals that, after activation on the
synaptic receptor, affect the neuronal activities of adjacent
cells. Based on electrophysiological studies, the enkephalins
appear to be the inhibitory neurotransmitters. Microionto-
phoretic application of enkephalins to locus coeruleus depressed
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the firing of neurons (hyperpolarization) in a dose-dependent,
naloxone-reversible manner (Pepper Henderson, 1980). The
hyperpolarization induced by enkephalins was thought to be due to
activation of calcium-sensitive potassium conductance (Williams
et al., 1982).
Opioid peptides were also shown to interact with other well-
known neurotransmitters. It has been reported that enkephalins
excite hippocampal neurons, an effect different from the
inhibitory effect on most other neurons of the brain. The
excitory effect was believed to be due to the inhibitory effect
of GABA-ergic inhibitory neurons (Zieglansberger, 1979). Apart
from this, the opioid peptides also show inhibitory effect in the
release of norepinephrine in rat cerebral cortex (Arbilla et al.,
1978).
Opioid peptides also interact with other peptidergic system.
An example is their interaction with substance P. Substance P
appears to be an excitory transmitter involved in central pain
transmittion (Jessel Iverson, 1977). Enkephalins were shown
to block the release of substance P (Terrenius, 1978).
2. Neurohormonal actions of opioids: The high concentration of
opioid peptides in the hypothalamic-pituitary axis suggests that
they may be involved in certain neuroendocrine functions.
Evidence of this came from studies of prolactin (PRL) and growth
hormone (GN) regulation in rat. It has been shown that B-
11
enodorphin, like other opiate alkaloids, is a potent stimulator
of PRL and GH releases in rat (Bruni et al., 1977). The opiate
induced PRL release may involve the dopaminergic system. Since
dopamine is believed to be the endogeneous PRL releasing
inhibitory factor and opioid peptides were found to be the potent
inhibitor of dopamine release (Van Loon et al., 1980), the
mechanism of opiate induced PRL release was thought to be
mediated through dopamine inhibition (Van Vugt et al., 1979).
Opioids effect on GH release in rat, on the other hand, is more
complex and may involve multiple neurotransmitter interactions
(Katakami et al. 1981a,b).
Opioid peptides are also active in the pituitary-adrenal
axis. The peptides, as well as opiate alkaloids, can inhibit the
cirrculatory level of ACTH, LPH and cortisol. This is presumably
modulated by corticotropin releasing factor (CRF) (Grossman
Besser, 1982).
The co-existance of dynorphin with vasopressin in the
posterior pituitary also leads to the speculation that it may
have some. action in water and salts homeostasis.
3. Clinical perspectives of opioid peptides: The possible
involvement of the opioid peptides in the modulation of pain
perception, in accupuncture analgesia and in mental diseases has
generated great interest. The high concentration of opioid
peptides and opiate receptors in the periaqueductal gray (PAG)
area, where electrical stimulation leads to analgesia, suggests
12
that the opioid peptides are endogeneous analgesic agents.
Similar line of evidence suggests that accupuncture analgesia may
also be mediated by the opioid peptides (Clement-Jones Rees,
1982)
Disturbances in the production of opioid peptides may lead
to the psychiatric diseases. In this respect, De Weid (1979)
has suggested that schizophrenia may be due to the results of a
deficiency in an opioid like peptide. Intravenous B-endorphin
injection to depressed patients was observed to be effective in
improving the symptoms of this disease (Berger et al., 1980).
Recent studies designed to measure the opioid peptide level in
the plasma and CSF of psychiatric patients, also provide
prilimiary support to this contention (Berger et al., 1981, Lo et
al., 1983).
I.3 Multiple opiate receptor concept
The concept of multiple opiate receptors was originally
proposed by Martin and his coworkers (1976). Based on the
pharmacological effects of opiates in humans and spinally
transected dogs, they were able to distinguish three types of
opiate receptors which they designated as mu, kappa and sigma.
Morphine is the prototype agonist for the mu receptor,
ketozocine for the kappa receptor while N-allylnormetozocine for
the sigma receptor. Each type of receptors has its characteristic
pharmacological specificity. In other words, these receptors
13
interact differently with a series of opiates and provoke
different pharmacoloigcal effects.
The multiple opiate receptor concept was further explored
after the discovery of the endogeneous opioid peptides. It was
found that the rank of order of potencies of the opioid peptides
is significantly different from that of the opiate alkaloids in
two pharmacological assays (Lord et al., 1977). It was observed
that opiates interact with two types of receptors: the mu
receptors, with which morphine preferentially interacts, appear
to predominate in the guinea pig ileum. The delta receptors,
which enkephalins preferentially interact, appear to predominate
in the mouse vas deferens.
In vitro biochemical characterizations of the binding of
opioids to the opiate receptors has also provided further
information in the classification of opiate receptor subtypes.
In homogenates of guinea pig brain, met-enkephalin and leu-
3
enkephalin were found to displace the binding of H-leu-
3
enkephalin more effectively than the binding of H-naloxone. In
contrast, morphine was more potent in displacing the binding of
3 3
H-naloxone than that of H-leu-enkephalin (Lord et al., 1977).
Similar results were obtained in other mammalian brain tissues.
In the past few years, efforts have been made in the
synthesis of enkephalin analogs that may help to differentiate
2 5
t'he receptor subtypes. For example, D-ala -D-leu -enkephalin
(DADLE), a leu-enkephalin analog, increases the potency 16-fold
14
i n the mouse vas def erens assay and 10-fold in the guinea pig
ileum assay due to a decreased in degradation of the analog
2
[ D-ala-(Kosterliz et al., 1980). Another enkephalin anolog,
4 5
McPae Gly-ol]- enkephalin is a highly selective ligand for
the mu-sites, being 220 times more active at mu-sites than at the
delta-sites (Kosteritz Paterson, 1981).
Another line of evidence supporting the view that opiate
receptor subtypes are morphologically distinct sites came from
some ingenious experiments on selective protection assays (Robson
Kosterlitz, 1979 Smith Simon, 1980 Kosterlitz et al., 1981
Chavkin et al., 1982). Selection protection experiments were
carried out by pre-incubating brain membrane with appropiate
unlabelled ligands that can selectively protect each receptor
subtype from the irreversible inactivating effect of alkylating
agents. Thus, DADLE, a ligand with high of f i my for delta
3
sites, protects the binding of H-DADLE more readily than that of
3
mu-selective ligand, H-dihydromorphine (DHM). In contrast,
3
unlabelled DHM is more potent in protecting the binding of H-DHM
3
than that of delta-agonist H-DADLE (Robson & Kosterlitz, 1979
Smith Simon, 1980).
Direct visualization of the existance of separate opiate
binding sites was obtained by the technique of autoradiography
(Goodman et al., 1980). By using selective radiolabelled ligands,
different patterns in the distribution of mu- and delta sites
within the central nervous system and peripheral tissue have been
15
observed.
Endogeneous opioids can bind receptor subtypes selectively.
For example, leu-enkephalin has a higher affinity for the delta-
than for the mu- receptor, and it is almost inactive against the
kappa sites. Recent evidence has also shown that dynorphin and
its related peptides interact selectively with kappa-sites
(Pfeiffer et al., 1981 Chavkin et al. 1982 Corbett et al.
1982). B-endorphin, on the other hand, appears to interact with
mu or delta sites with equal potency but have little affinity for
the k-sites (Kosterlitz et al., 1982). The difference in
selectivity of opioid peptides to opiate receptor subtypes may
account for the specific physiological function of the peptides.
1.4 Molecular properties of opiate receptors
In parelle-l to the work on the classification of opiate
receptors, much work had been done to elucidate the molecular
nature of receptors heterogeneity.
The opiate receptors are highly susceptible to various
proteolytic enzymes (Pasternak Synder, 1975 Zukin Zukin,
1981) and protein-inactivating agents (Pasternak et al. 1979
Robson Kosterlitz, 1979 Smith Simon, 1980). Recent work on
the solubilization of opiate receptor has further demonstrated
that opiate receptor is a glycoprotein (Gioannini et al., 1982).
On the other hand, it has also been suggested that there may be
an acidic lipid componant in the opiate receptors. In support of
16
this, opiate binding activity can be readily inhibited by
phospholipase treatment. (Pasternak Synder, 1975). Loh and his
coworkers have continously reported that opiates can
stereospecifically bind to certain acidic lipid such as
cerebroside sulfate (Loh et al., 1978 Smith Loh, 1979 Lee &
Smith, 1980). However, it has been argued that phospholipase
treatment may release lysophosphatides which can in turn
inactivate opiate receptors (Ruegg et al., 1982). Thus, up to the
present stage, there is no direct evidence to support the view of
the direct involvement of lipid.
Another aspect of studies in the molecular properties of
opiate receptor came from the multiple effects of metal ions on
opiates binding affinities to receptors. Initial studies had
shown that sodium ions differentially enhance the affinity of
antagonist binding while reducing the affinty of agonist binding
to receptor sites (Pasternak et al., 1975 Simon et al., 1975
Sima ntov et al., 1976). It was suggested that sodium ions may
induce a conformational change from a agonist-selective state to
an antagonist-selective state (Simon et al., 1975).
On the other hand, the Na and GTP effect in opioid-induced
inhibition of basal and PG-stimulated adenyl cyclase has also
been recognized (Blume et al., 1979). GTP alone, or in the
presence of Na, was shown to reduce agonist binding to the
opiate receptors without affecting antagonist binding (Blume,
1980 Childer Synder, 1980). This reduction in agonist binding
17
+2-
can be antagonized by Mn (Blume, 1980).
In the studies.of divalent ions effect on opiate receptor
binding, Sadee et al. (1982) demonstrated that antagonist binding
+2 +2 +2
is reduced by Ca and Mg and is stabilized by 1 mM Mn
Recently, it has also been reported that metal ions can
differentially interact with different opiate receptor subtypes.
Pfeiffer (1981) reported a selective increase in delta-agonist
+2
but not in mu-agonist binding by Ca Similar effects were
+2 +2
observed for Mn and Mg (Bowen et al., 1981 Koualou et al.,
1982).
The fact that opiates can protect the receptor sites from
inactivation by N-ethylmaleimide (NEM) treatment suggests that
thiol groups are probably involved in receptor binding (Smith
Simon, 1980). Thiol and disulfide groups were also shown to be
involved in receptor clustering, which occur after opioid
agonist and antagonist binding. Cluster induced by agonists but
not those induced by antagonists, could be dispersed by reducing
agents after removal of bound opiates (Hazum et al., 1980).
1.5 Use of cell culture in opiate receptor studies
The use of cell cultures in biochemical research has
yielded important information on complex physiological functions
that can not be easily obtained from animal studies. The great
advantage of this technique is that it offers a homogeneous
populations of cells of virtually identical genetic. make-up in a
18
constant controlled environment. Cells can thus be easily
manipulated and the result obtained can easily be interpreted.
Studies of opiate receptor function with cell culture did
not commence until Klee and Nirenberg (1974) initially reported
that the neuroblastoma x glioma hybrid cell line NG108-15 contain
a high density of opiate receptors resembling that of the brain
opiate receptors. Subsequent experiments on this cell line have
provided important insights in the actions of opiates. It was
found that the opiate receptor are functionally coupled to the
adenyl cyclase system (Sharma et al.1975a; Traber et al., 1975).
This coupling of adenyl cyclase activity was postulated to
correlate with the development of opiate tolerance and withdrawal
symptoms (Sharma et al., 1975b)
In addition to the presence of opiate receptor, the
neuroblastoma x glioma cells also contain other membrane
receptors that are functionally coupled to adenyl cyclase. Those
being best characterized are the prostaglandin (PG) receptor,
adenosine receptor, adrenergic receptor and cholinergic receptor.
In view of this, these cells can thus provide an attractive model
in studying the interaction of neurotransmitter receptors under
defined in vitro conditions.
1.6 Approach of membrane lipid modification to study membrane
related function
19
The importance of lipid composition in biological membranes
has been well documented. Changes in membrane physical
properties has been shown to produce changes in membrane-related
functions. Since opiate receptors are known to be embedded in a
membrane of lipid bilayer, it is reasonable to suggest that
changes in membrane lipid composition may affect opiate receptor
binding characteristics. After years of intense studies on
opiate receptor function, there is still little known about the
structural characteristics of the receptor. In order to obtain
additional understanding on this, efforts have been made to
isolate pure opiate receptor, hoping to find some structural
information on the receptor molecule. Another approach to this
problem is to investigate the receptor binding characteristics
when the membrane lipid composition is perturbed. The use of
cell culture offers the capability of modifying membrane acyl
composition more rapidly than can be achieved in animal system
using dietary control. In addition, cell culture studies can
also minimize the variation frequently observed between
individual animals.
I.7 Aim of the present study
In the present study, the neuroblastoma x gloma hybrid cells
NG108-15 were used to study lipid effects on opiate receptor
binding characteristics. Effects of lipids on membrane receptors
binding by unsaturated fatty acids exposure has recently been
reported (Ho Cox,1982 McGee Kenimer, 1982). It was found
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that the opiate binding was significantly reduced after exposure
of cells to unsaturated fatty acids. Scatchard analysis of the
binding indicated that the reduction in opioid binding was
primarily due to the loss of binding capacity without affecting
the binding affinity.
The present study aims to find the mechanism underlying this
reduction caused by unsaturated fatty acids. The project has
been focused on comparing this reduction of opioid binding with
other membrane receptor and membrane-related functions.
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CHAPTER II
GENERAL PROPERTIES AND RECEPTOR BINDING CHARACTERISTICS
OF NEUROBLASTOMA X GLIOMA HYBRID NG108-15
II.1 Introduction
The neuroblastoma x glioma hybrid cell line NG108-15 was
originally developed by Hamprecht by the fusion of a mouse
neuroblastoma clone N18TG2 with a rat glioma clone C6-BU-1.
Because of the neuronal origin of the hybrid, the cells possess
many interesting neural properties that make them a useful model
for neurobiological studies. In particular, these cells possess a
large number of opiate receptors as compared to their parent cell
lines (Klee Nirenberg, 1974). During the past decade, these
hybrids have been used to investigate opiate actions as well as
other neurobiological problems. Apart from the presence of
opiate receptor, the hybrids also contain other neurotransmitter
receptors. Those being best characterized are those functionally
coupled to the adenyl cyclase system. These receptors include
the prostaglandin (PG) receptor, adenosine receptor, adrenergic
receptor and cholinergic receptor.
In connection with the characterization of the opiate
receptors in the hybrids, much work has been done which focused
on its relation with adenyl cyclase. Opiate receptor was shown
to be coupled to adenyl cyclase in an inhibitory manner (Sharma
et al., 1975a). Opiates can inhibit both basal and PG-stimulated
CAMP level by a receptor-mediated process.
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It was also known that the opiate receptor in the hybrids
was primarily the delta (enkephalin) type of receptor (Chang
Cautrecasas, 1979).
In the present studies, some experiments concerning the
properties of opiate binding characteristics of the cells were
carried out. Our data confirmed the existence of the delta type
of receptor in these hybrids and also provided additional
evidence indicating possible existence of high affinity sites for
kappa-agonist. Studies on the down regulation o of opiate
receptors in these cells by various opiates were also
investigated. Evidence are also presented to support the view
that the hybrid cells can synthesize opioid-like comPounds.
11.2 Materials and Methods
A. Preparation methods
1. Preparation of culture medium
The growth medium used for the cell culture studies was
Dulbecco's Modified Eagle Medium (DMEM, Gibco). The medium was
prepared with double-distilled water supplemented with 3.7g/1
sodium bicarbonate, 110 mg/1 pyruvate. The medium was sterilized
by passing through a 0.45 um Millipore filter under pressure and0
stored at 4 C. Sterility was checked by aliquoting serveral ml
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of medium in a sterilized plastic tube and cultured at 37°C for
at least 2 days. Just before use, each 500 ml of medium was
supplemented with 5 ml 100X stock HAT solution, 5 ml of
Penicillin-Stretomycin solution (Gibco 5,000 units penicillin G
and 10,000 mcg sodium stretomycin per ml) and 25 ml of calf
serum to make a final concentration of 5% (v/v).
2. Preparation of HAT solution
The 100X stock HAT solution containing 10 mm hypoxanthine,
0.1 mM ami nopter i n and 1.2 mM thymidine was prepared by adding
136.1 mg hypoxanthine, 4.4 mg aminopterin and 29.06 mg thymidine
in 100 ml double distilled water, adjusting pH to 11 with diluted
NaOH. The solution was heated just below boiling until all the
ingredients were dissolved. The solution was then sterilized by
Millipore filtering and stored at 4 °C in a dark bottle.
3. Cell culture methods
The mouse neuroblastoma x rat glioma hybrid clone NG108-15
was grown in Dulbecco's modified Eagle medium (DMEM) containing
5% calf serum (Gibco), penicillin/streptomycin (10 units/ml,l0
ug/ml, Gibco) and 0.1 mM hypoxanthine, 1 uM aminopterin and
12 uM thymidine. Cells were continously subcultured in Corning
2 2
T-75 cm or T-150 cm culture flasks in a humidified atmosphere
at 37°C. Cells were fed when the medium pH was below 7.
After reaching confluency, the cells were harvested in the same
medium by gentle agitation. The cells were then washed three
24
times with Dl solution (137 mM NaCl, 5.4 mM KC1, 0.17 mM Na HPO,
2 4
5.5 mM glucose, 0.22 mM KH PO). For intact cell binding, cells
2 4
were also counted by a hemocytometer and viability of cells were
estimated by the Trypan Blue method. Viability of cells usually
exceeds 85%. For later use, cells were usually stored in a Tris-
sucrose medium (10 mM Tris-HC1, pH 7.4, 1 mM MgCl, 0.32 mM
0 2
sucrose) at -20 C. The opioid binding activity of these cells
remains unchanged for up to 3 months.
4. Preparation of cell membrane homogenates
Either freshly harvested cells or thawn cells were used for
the preparation of membrane homgenates. Cells were suspended in
0
10 ml ice-cold 10 mM Tris-HC1( pH 7.4) at 4 C, and then
disrupted by sonication( Ultrasonics, model w200R) for 20 sec
0
at 0 C. After standing in an ice-bath for 20 min, the cell
homogenate was centrifuged for 10 min at 10,000 x g. The pellet
was then washed once with 10 mM Tris-HC1. The pellet thus
obtained was then suspended in 50 mM Tris-HC1 to a protein
concentration of 500-1000 ug/ml. This membrane suspension was
used for opioid binding.
5. Extraction of opioid-like material from NG108-15 cells
The opioid-like compounds from the cells were extracted by
methanol:0.1 N HCl (1:1, v/v). Cells were first disrupted by
0
sonication and then boiled in methanol:HC1 (80 C) for 15 min.
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The cell homogenate thus obtained was centrifuged at 10, 000 x g
for 20 min. The superna to was pipetted off and dried either in a
.speed vac device (Servant) or by lypholization. The extract was
then resuspended in RIA buffer for B-endorphin radioimmunoassay.
B. Assay methods
1. Radioreceptor assay of cell membrane homogenates
a. Opiate receptor assay
The following radiolabelled opiates were obtained from New
3 2 5
England Nuclear(NEN): H-D-ala -D-leu -enkephalin (DADLE, 43.6
3 3
Ci/mmol), H-ethykecyclazocine (EKC, 16.4 Ci/mmol), H-dihydro-
3 2 4 5
mophi ne (DHM, 84.5 Ci/mmol). H- (D-ala -D-MePhe -Gly-ol)-
enkephalin (DAGO, 32 Ci/mmol) was purchased from Radiochemical
Centre, Amersham, U.K.
i. Saturation binding assay: Binding was performed in a final
volume of 0.5 ml 50 mM Tris-HC1 buffer (pH 7.4). 0.4 ml of mem-
brane homegenate with a protein content of 150-250 ug was mixed
with 0.1 ml tritiated opiates in the range of 0.6-20 nM final
concentration. Incubation was carried out at room temperature for
one hour. Bound and free radioactive ligands were separated by
rapid suction filtration on Whatman GF/C filters and the filter
was washed three times with 4 ml ice-chilled 50 mM Tris-HC1
buffer. Seven ml scintillant (toluene:Triton X. 2:1 v/v, 4 g/l
PPO, 0.4 g/l POPOP) was added to the dried filter and the mixture
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was shaken for 1 hr. Radioactivity retained in the filter was
determined by liquid scintillation spectrometry (Beckman LS 2000)
at a counting efficiency of 40%. Nonspecific binding was
determined by the radioactivity bound in the presence of 1 uM of
'cold' ligand.
ii. competitive receptor assay: The assay was essentially simi-
lar to the saturation binding assay except that fixed concen-
tration of radioactive ligand (1-2 nM) was used. 0.5 ml assay
mixture containing various concentration of3 opiates (0.01-
1000 nM), 2 nM H-opiate and cell membrane ho megena to was
incubated at room temperature for 1 hour. Bound and free activity
was separated by GF/C filteration method as described in the
previous section.
b. Alpha-adreneryic receptor assay
The binding assay was modified f rom that of Kahn et a 1
3 3
(1982). H-para-aminoclonidine( H-PAC 40 Ci/inmol NEN) was
used as the radiolabelled agonist. The binding was measured in
50 mil Tris-HCl buffer (pH 7.4) containing 1 mm MgCl. For one ml
2assay mixture 0.5-1.0 mg protein and various 3
ration of H-PAof H-
PAC (0.6-20 nM) was used. Incubation was carried out at room
temperature in the dark for 40 min. Bound and free 3
H -PAC was
separated by rapid filtration using Whatman GF/C filter. The
filter was then washed three times with 4 ml ice-chilled Tris-HC1
buffer. Radioactivity retained in the filter was measured by
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adding 7 ml scintillant and counted by a liquid scintillant
counter at a counting efficiency of 40%
c. Cholinergic receptor assay:
3
H-quinuclidinyl benzilate (QNB 33.1 Ci/mmol, NEN) was used
3
as radioligand to label muscarinic receptors. Saturation H-QNB
binding was performed according to method of Klein et al. (1980).
One ml assay medium (50 mM Tris-HCl, pH 7.4) containing 300-
3
500 ug cell membrane and various concentration of H-QNB was
incubated at room temperature in the dark for 90 minutes,
Nonspecific binding to membranes was determined in the presence
of 1 uM atropine. Bound and free ligand were separated as
described in the opioid binding assay. The radioactivity retained
in the filter was counted by liquid scintillantion spectrometry
at a counting effecicency of 40%.
2. Intact cell receptor assay
For the intact cell receptors assay, cells were freshly
prepared and washed three times with D1 solution. Cells were
counted by a hemocytometer and viability was determined by Trypan
Blue exclusion method. Cells were suspended in Krebs-Ringer
Hepes buffer (KRHB 110 mM NaCl, 5 mM KC1, 1 mm MgCl, 1.8 mM
2
CaCl, 25 mM glucose, 55 mM sucrose, 10 mM Hepes, pH 27.4) at a
2 6
concentration of 1 x 106 cells/ml. For saturation opiate receptor
6
assay, 1.0 ml assay mixtures containing 1 x 106 cells and various
3
concentraton of 3 H-opiate were incubated in a shaking water bath
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at 37 C for 20 min. After then, the content of the assay mixture
was immediately filtered over a Wha tman GF/C filter under vacumn.
The filter was washed three times with 4 ml ice-chilled KRHB
buffer. Filters were then dried in an oven and 7 ml scintillant
was added. After shaking for 2 hours, the radioactivity retained
in the filter was measured by a liquid scitillation counter at a
counting efficiency of 40%. Similar procedure was adopted for
H-PAC binding assay.
3. Protein determination
Protein was determined by the method of Lowry et al. (1951)
using bovine serum albumin (0.02-0.2 mg/ml) as standard. To
200 ul of sample, 2 ml of reagent A (2% CuSO: 4% Na -K
4
tartrate: 3% Na CO 1:1:48, v/v) was added. After standing at
2 3
room temperature for 15 min, 200 ul of regeant B (Folin:H 0 1:1,
2
v/v) was added and mixed vigorously. The O.D. of samples were
then read at 750 nm after standing for 45 min. For membrane
protein determination, membrane was first digested with 1 N NaOH
for at least two days. Samples were then neutralized by 1 N HC1
just before assay.
4. Radioimmunoassay of B-endorphin
a. Iodination of B-endorphin




mixed with 1 mCi carrier free I (Amersham) in 25 ul 50 mM
phosphate buffer (pH 7.4). Six ul of chloramine-T solution (3.53
mg /ml buffer) was added and mixed vigorously for 5 sec. Twenty
ul of B-mercaptoethylamine (10 ng/ 100 ul) and 50 ul 5% BSA in
PBS were then added to stop the reaction. The iodination mixture
was then loaded onto a LH-20 column (10 x 1 cm) and eluted with
1 M pyridine, 0.5 M acetic acid. 1 ml fractions were collected
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and I-B-endorphin was eluted between fraction 4 and 5.
b. Radio immunoassay
Samples were dissolved in 0.1 ml RIA buffer (0.01 M phos-
phate buffer, pH 7.4 0.15 M NaCl 0.1% BSA 0.1% EDTA 0.01%
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thimerosal). It was then mixed with 0.1 ml I-B-endorphin
(15,000 cpm/ 0.1 ml) and 0.1 ml antiserum for B-endorphin (RB100,
1: 12,000 final). The mixtures were then incubated at 4 C for 24
hours, 0.1 ml rabbit IgG (0.3 m g/ml) and 0.1 ml goat anti-
rabbit IgG (P4GARGG diluted 1:14) were added and incubation was
continued at 4 C for 24 hours. 1 ml of ice-colded phosphate
buffer saline (PBS 0.01 M phosphate buffer, pH 7.4 0.15 M NaCl)
was added and the suspension centrifuged at 6,000 rpm for 30
minutes. The supernatant was then poured off and the
radioactivity in the pellet counted in a gamma-counter
(Beckman). Standard h-B-endorphin (10-0.01 ng/tube) was used for
calibration.
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II.3 Results and Discussions
A. Morphology of the NG108-15 cells under light microscope
The NG108-15 Cells were grown in Dulbecco's Modidified
Eagle's Medium (DMEM) supplemented with 0.1 mM hypoxanthine, 1 um
aminpterin and 12 uM thymidine (HAT). The purpose of exposing
cells in HAT medium was to select the hybrid clone against the
parent cell lines as the parent cells are unable to survive in
the presence of HAT. Fig. 2.1 shows the morphology of the hybrid
cells under light microscope. The cells are rounded, occasionally
grow in cluster, and can readily attach on the culture flask as
:nonolayer. A few of them may form short neurite-like processes
probably for cell-cell communication. However, if the cells were
seed in low density, long and thick processes could be seen and
the growth rate was significantly retarded. Normally, the cells
are detached from the layer when cells are in mitotic phase.
A change of pH in culture medium could affect the morphology
of the hyrid. Cells form clusters and growth was inhibited
as the medium became alkaline. If the condition remained in more
than 2 days, cells will finally die. On the other hand, these
cells are relatively tolerent to acidic pH of the medium.
B. Opiate receptor binding characteristcs of NG108-15 hybrids
Klee and Nirenberg (1974) using 3H-dihydromorphine (DHM)
first demonstrated the existence of saturable specific opiate
Fig. 2.1 Morphology of neuroblastoma x glioma hybrid NG108-15
cells under light microscope. Cells were grown in
Dubelco's Modified Eagle Medium (DMEM) supplemented
with HAT and 5% of calf serum as described in Materials
2 2
and methods in either Corning 75 cm or 150 cm flasks.
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binding sites in NG108-15 cells. Later, by competitive opioid
3
binding assay using H-leu-enkephal i n as primary l igand, Gerger
et al. (1978) have characterized the binding properties of most
opiates to these cell membranes. Opiate receptor in NG108-15
cells has been shown to be of delta-type receptor (Chang
Cuatrecasas, 1979). In the present study, highly-selective
radioligands are used to characterize the opiate receptors of the
hybrids.
Fig. 2.2 shows the binding of 3H-D-ala2-D-leu5-enkephalin
(DADLE) to the cell membrane homogenate. Nonspecific binding was
determined in the presence of excess DADLE (1 UM). The
percentage of nonspecific binding to total binding was less than
3
10%. H-DADLE specific binding was shown to be saturable at
concentration as low as 10 nM. Scatchard analysis of the binding
indicates that the binding is homogeneous with a dissociation
constant (Kd) of about 2.9 nM and total specific binding (Bmax)
of about 1500 fmol/mg membrane protein.
Specific 3H-DADLE binding can also been demonstrated by
3
intact cell assay. Fig. 2.3 shows a typical H-DADLE saturation
binding curve to intact cells. It was shown that the binding is
virtually similar to that of membrane receptor binding in terms
of binding affinty. Total number of receptors sites per cell as
estimated by Scatchard analysis was about 120,000 sites.
In order to confirm the opiate receptor specificity of the
3
hybrids, binding with H-DHM and a new mu-selective opiate
Fig. 2.2 3H-D-ala2-D-leu5-enkephalin (DADLE) specific binding to
3
NG108-15 membranes of increasing concentration of H-
DADLE. cells membranes (0.25 mg of protein) were
incubated for 60 min at room temperature with various
3
concentrations of H-DADLE. Nonspecific binding was
determined in the presence of 1 uM DADLE. Points shown
are from a single experiment, performed in triplicate,
with standard deviations 5% of the mean. Repeated
experiments show similar results. Inset shows the Scat-
chard plot of saturation data. (Borax= 1.5 pmol/mg
protein Kd=2.8 nM r=0.98).
3 H-DADLE Cone., nM
Fig. 2.3 3H-D-ala2-D-leu5-enkephalin (DADLE) specific binding to
6
intact NG103-15 cells. Cells (1 x 10 cells) were
0
incubated for 20 min at 37 C with various
3
concentration of H-DADLE. Nonspecific binding was
determined in the presence of 5 uM DADLE. Points shown
are from a single experiment, performed in triplicate,
with standard deviations less the 5%. Inset shows the
6
Scatchard plot of saturation data. (Bmax =200 fmol/10
cells Kd= 3.3 nM r=0.98).
3 H- DADLB, n M
3 2 4
analog, H-(D-ala- -D-MePhe -G1y-ol)-enkepha1in (DAGO) was carr-
3
ied out. H-DHM binding was demonstrated to be of low affinity
3
(Fig. 2.4) and 3H-DAGO specific binding was undetectable under
our assay conditions (results not shown). This demonstrates
unequivocally that the hyrids lack mu-receptor subtype.
Another approach to demonstrate the nature of the opiate
receptor subtype in the hybrid cells was by competitive binding
assay. Fig. 2.5-7 show the competitive displacement curves of
various opiates and opioid peptides on cell membrane homognates
3
using H-DADLE (2 nM) as primary ligand. DADLE, leu-enkephalin
3
and met-enkephalin were shown more potent in displacing H-DADLE
binding than that of morphine, naloxone, methadone and DAGO. The
D-isomer of levorphanol, dextrorphan, was found totally inactive
3
in displacing H-DADLE binding, indicating the binding is
stereospecific. Table 2.1 summaried the binding data of the
competitive binding assay. These results further support the view
that the receptors in these hybrid cells are enkephalin-
selective.
In order to evaluate if there is any kappa binding sites in
3
the NG108-15 hybrids. H-ethy1ketocyclazocine (EKC) specific
binding was performed. As indicated in Fig. 2.8, the binding was
saturable and Scatchard analysis indicate that the binding is
homogeneous with an apparent Kd of 8.5 nM. By comparing the
3 3
total H-EKC specific binding capacity with that of H-DADLE
3
(Fig. 2.2), it is possible that H-EKC may actually bind to the
3Fig. 2.4 H-dihydromorphine (DHM) specific binding to intact
cells. Cells were incubated with various concentrations
3
of H-DHM and assayed as described in Materials
Methods. Nonspecific binding was determined in the
presence of 0.6 mM morphine. Points shown are means of
triplicate determinations with standard deviations
less than 10%.





Competitive inhibition of H-DADLE (2 nM) binding to
NG108-15 cell membranes by DADLE methadone
and dextrorphan
3
Competitive inhibition of H-DADLE (2 nM) binding to
NG103-15 cell membranes by EKC naloxone and
morphine
3
Competitive inhibtion of H-DADLE (2 nM) binding to
NG108-15 cell membranes by etorphine Met-
enkephalin (O), DADLE (A), Leu-enkephalin and
DAGO
Cone, of Oplatt, nM
Cone, of Oplata, nM
Opiates Cone, n M
Table 2,1 Potencies of opiate drugs in inhibiting H-DADLE (2 nM)
binding to NG108-15 cell membrane homogenates.
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IC50 is the concentration of the drugs required to
3
inhibit 50% of H-DADLE (2 nM) specific binding.
Fig. 2.8
3
H-ethylketocyclazocine (EKC) specific binding to
NG108-15 membranes. Cell membranes (0.5 mg of protein)
t
were incubated for 60 min at room temperature with
3
various concentrations of H-EKC. Nonspecific binding
was determined in the presence of 1 uM EKC. Points
shown are from a single experiment, performed in tri¬
plicate with standard deviations less than 5% of the
means. Inset shows the Scatchard plot of saturation
data. (Bmax= 1.3 pmol mg; Kd= 3.3 nM; r=.96)
3 H- E K C Cone. f n M
3same population of opiate receptors as that of H-DADLE.
In order to further characterize the H-EKC binding to these
hybrid cells, excess delta-agonist DADLE (1 uM) was included in
the determination of total binding. Fig. 2.9 shows the binding
3
of H-EKC binding carried out in this way with intact cells. As
shown in the Scatchard plot, the saturation binding curve is
biphasic, indicating either a heterogenity in binding sites or a
negative cooperitive effect. This experiment provides some
evidence of the existance of high affinity sites for kappa-
agonist in the cells after suppressing the delta-receptor sites
with excess delta-agonist.
In summary, the NG108-15 cells probably contain a high
density of delta opiate receptor with little, if at all, mu
receptors. Some kappa receptor may also exist in these cells.
C. Down regulations of opiate receptors
It has recently been reported that when NG108-15 cells were
exposed to opiate agonists for either short-term or chronic
treatment, a reduction in opiate receptors would be induced.
(Chang e_t a_l., 1982; Law e_t a_l., 1982; 1893). This reduction in
opiate binding, or the so-called down regulation of the opiate
receptors, was postulated to correlate with the effects of the
opiates on adenyl cyclase activity. The relationship between
adenyl cyclase and opiate receptors turnover has been used to
explain the complex phenoemenon of opiate tolerance and
Fig. 2.9
3
H-ethy1ketocyclazocine (EKC) specific binding to
6
intact NG103-15 cells. Cells (1 x 10) were incubated
o 3
for 20 min at 37 C with various concentration of H-
EKC in the presence of 1 uM DADLE. Nonspecific binding
was determined in the presence of 5 uM EKC. Points
shown are from a single experiment, performed in
triplicate with standard deviations less than 5% of
the means. Inset shows the Scatchard plot of saturation





In order to confirm the theory of down regulation in the
NG108-15 cell line, studies on the effect of opiate exposure were
3
performed. Fig. 2.10 shows results of H-DADLE binding after
cells were exposed to 10 um of various types of opiates for
24 hr. In order to remove bound opiates before assay, cell
0
membranes were incubated at 37 C for 30 min and then washed
three times with 10 mM Tr is-HC1 buffer (pH 7. 4). As shown in
Fig. 2.10, preincubation with morphine, naloxone, methadone, as
3
well as dextrorphan, had no effect in reducing H-DADLE binding.
3
On the other hand, H-DADLE binding was significantly inhibited
after exposure to levallorphan and ethylketocyclazocine (EKC).
To demonstrate that down regulation can also be induced by
opioid peptides, the experiment was repeated by exposing the
hybrid cells to 100 nM DADLE at different periods of time. As
3
shown in Fig. 2.11, specific H-DADLE binding was rapidly
reduced after 2 hr of DADLE exposure and gradually flattened out
after 4 hr. This result confirms those reported in the literature
(Chang et al., 1982). The loss of receptors is unlikely due to
artifacts since cells harvested at zero time point bind as much
3
H-DADLE as those which were not incubated with cold DADLE.
In order to demonstrate that the effect of DADLE on receptor
down regulation is agonist specific, the antagonist, naloxone was
3
used to block the effect of DADLE. As shown in Fig. 2.12, H-
Fig.2.10 Reduction of 3-DADLE (2 nM) binding to NG108-15 cell
membranes after cells were grown in the presence of
opiates for 24 hr. The opiates used are morphine (mor),
naloxone (nal), methadone(meth), dextrorphan (dex),
levallorphin (lev), ethylketocyclazocine (EKC) at 10 uM
concentrations. Results are presented as % of the
control value (514 fmol/mg of protein). Values are
means of triplicate determinations with standard













Fig. 2.11 Effect of DADLE exposure of cells 3
on H-DADLE specific
binding to cell membranes. Cells were exposed to 100 nM
DADLE for different periods of times. Extensively
washed membranes were then prepared and 3
H-DADLE (2 nM)
binding was assayed as described in Materials &
Methods. Points shown are means of triplicate












Reduction of H-DADLE (2 nM) specific binding to NG108-
15 cell membranes after cells being exposed to DADLE
(200 nM) for 2-4 hr and antagonism of naloxone (5 uM)
in DADLE-induced opioid binding reduction. Points shown
are means of triplicate determinations with standard
deviations less than 5%. Results are presented as the%
of control opioid binding (258 fmolmg). cells
exposed to 200 nM DADLE; cells exposed to 5 uM




DADLE binding in cells grown in the presence of naloxone (2 um)
did not significantly different from the control. In contrast,
3
H-DADLE binding was significantly reduced when cells were grown
in the presence of DADLE (200 nM). On the other hand, when cells
were grown in the presence of DADLE as well as naloxone, the
3
inhibition effect on H-DADLE binding induced by DADLE can be
partially abolished. This experiment confirms that opiate down
regulation of receptors is an agonist effect and the effect can
be antagonised by the presence of excess antagonist.
D. The hybrid cells can synthesize ir-B-endorphin
One of the neuronal properties of the hybrid cells is their
ability to synthesize a number of enzymes for the biosynthesis of
neurotransmitters. An example of this is the choline
acetyltransferase activity, an enyzme required for the synthesis
of acetycholine. In conjunction with the ability to synthesize
acetycholine, the NG108-15 cells have been shown to possess
acetycholine receptors (muscarinic). Thus, by analogy it is
possible that these cells may also synthesize opioid-like
compounds for their opiate receptors. Attempts to identify and
characterize opioid-like substances from the hybrid cells have
been reported (Glaser et al., 1980, 1982). The nature of the
opioid-like substances found was shown to behave like leu-
enkephalin or met-enkephalin.
In the present study, we have also found that the hybrid
cells can synthesize an immunoreactive B-endorphin-like
36
2
substance. Eight 75 cm flasks of cells (approx. 3.2 x 10 7 of
cells) were used to extract opioid-like compound as described in
the materials and methods. Radioimmunoassay was used to monitor
B-endorphin activity. As indicated in Fig. 2.13, materials
extracted from the cells show crossed reactivity with the B-
endorphin specific antiserum. The slope of the binding inhibition
curve is essentially parallel with that of the standard peptide.
6
According to our data, the B-endorphin equivalent per 10 cells
is estimated to be about 4.1 fmoles.
Since the antiserum used (RB 100) was directed against
residues 14-27 of the B-endorphin molecule and it does not cross-
react with leu-enkephl in and met-enkephal in. The B-endorphin-like
compound that we detected is probably different from those
characterized by Glaser et al. (1982). The present finding,
together with those reported in the literature, suggests that the
NG108-15 cells can synthesize a wide spectrum of opioid-like
peptides. In this respect, the synthesis of opioid-like
substances by the hybrid cells might be of importance for the
regulation of opiate receptor turnover.
E. Other membrane receptor binding characterisics of NG108-15
cells.
Apart from the opiate receptors, the NG108-15 cells also
contain other neurotransmitter receptors. Example of these
include the a-adrenergic receptor and the acetycholine
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Fig.2.13 Inhibition of the binding of -B-endorphin to an
anti-B-endorphin antiserum (RB 100) by B-endorphin
( ) and the NG108-15 cell extract(). The dilution
of antiserum was 1:12,000. B/Bo was defined as the
ratio of radioacivity specifically bound to the
antiserim in the presence of sample to the
radioactivity specifically bound in the absence of any
opioid compound. The total specific bound
radioactivity was 5,300 cpm. Points repesent the mean
of d ulplicate determinations. Cells extracts from 8 x
2 7
75 cm (3.2 x 10 cells) were dissolved in 500 ul RIA
buffer. 200 ul were serially diluted two-fold at a time
to a final ratio of 1:32.
Cone, of B-«ndorphin p rigtube
Cone, of B-«ndorphln p ngtub«
(muscarinic) receptor. In this section, some binding
characteristics of a-adrenergic and muscarinic receptor of the
3
nybrid cells were investigated. H-para-aminoclonidine (PAC), an
a -adrenergic agonist, was used as the radioligand for the
2
binding of adrenergic receptor. Fig. 2.14 shows the saturable
3
specific binding of H-PAC to the cell membrane homogenates.
Nonspecific binding was determined in the presence of 0.1 mM(-)
norepinephrine (NE) or 1 uM phentolamine. Nonspecific to the
total binding was determined to be as high as 40%. Binding is
saturable at concentration of about 20 nM. Scatchard analysis
shows that the binding is homogeneous with an apparent Kd of 1.4
nM and the maximum binding sites of about 22 fmolmg protein.
The apparent Kd obtained by us is similiar to that reported by
Kahn e_t a_l_. (1982), however, our Bmax is about 6. times lower than
theirs. The reason for this is unknown. Presumably it may be due
to different culture or assay conditions.
3
In the muscarinic receptor assay, H-quinuclindiny1
benzilate (QNB) was used for labelling the receptor. Fig. 2.15
3
shows the specific H-QNB (0.5-20 nM) binding to the hybrid cells
membranes homongenates. The binding is saturable and homogeneous
with an apparent Kd of 1.8 nM and Bmax of 100 fmolmg protein.
3
The binding affinities of H—QNB in NG108—15 cells were
compared with that obtained from rat brain homogenates
(Fig. 2.16). Significant differences were observed (rat kd
0.18 nM, Bmax= 618 fmolmg vs. NG108-15 cells Kd= 1.8 nM, Bmax
Fig.2 .1
13
H-para-aminoclonidine (PAC) specific binding to NG108-
15 membranes. Cell membranes (0.58 mg of protein) were
incubated for 40 min at room temperature with various
3
concentrations of H-PAC. Nonspecific binding was
determined in the presence of 1 uM phentolamine. Points
shown are from a single experiment, performed in
triplicate. Inset shows the Scatchard plot of
saturation data (Bmax= 23 fmolmg; Kd= 1.5 nM; r=
sj«
3 H-PAC Cone. ,nM
Fig. 2.15
3
H-quinuclidiny1 benzilate (QNB) specific binding to
NG108-15 membranes. Cell membranes (0.5 mg of protein)
were incubated for 90 min at room temperature in the
3
dark with various concentrations of H-QNB. Nonspecific
binding was determined in the presence of 1 uM
atropine. Points shown are from a single experiment,
performed in triplicate, with standard deviations less
than 5%. Inset shows the Scatchard plot of saturation
data (Bmax= 100 fmolmg; Kd= 1.8 nM; r=0.94).
H-QNB Cone., nM
3Fig. 2.16 H-quinuclindiny1 benzilate (QNB) specific binding to
rat brain (minus cerebellum) homogenates. Membranes
were prepared by homogenizing the brain in ice-cold
0.32 M sucrose. The homogenates were centrifuged at
1,000 x g for 10 min. The supernatant was then
centrifuged at 10,000 x g for 20 min. The pellet was
washed two times with 50 mM Tris-HCl (pH 7.4) by
centrifugating at 10,000 x g for 20 min. The pelet was
then resuspended in 50 mM Tris buffer at a protein
concentration of 2 mginl. Binding assay was performed
as described in Materials Methods. Points shown are
means of triplicate determinations with standard
deviations less than 10%. Inset shows Scatchard plot of
saturation data (Kd= .18 nM; Bmax= 618 fmolmg of
protei n).
3 H-QNB Cone., nM
103 fmolmg). Moreover, when compared with data reported by
Klein et al. (1980). our Kd for H-OMR bindina wa .q 1 R fold hi nhpr_
This apparent discrepency in Kd value when higher concentration
of H-QNB was used suggests that different receptor entities or
different receptor conformation may be involved.
CHAPTER III
EFFECTS OF UNSATURATED FATTY ACIDS EXPOSURE
ON OPIATE BINDING ACTIVITIES OF THE NG103-15 HYBRIDS
III.l Introduction
It is well known that biological membranes are crucial in a
number of cellular processes. The diverse functions of different
cells and different organelles are in part accountable by the
great diversity of membrane lipid and protein compositions. For
example, the response of a target cell to hormone or
neurotransmitter is frequently dependent on receptor which
detects the presence of the ligand and transmits the message
through the membrane.
Membrane proteins are believed to intercalate through the
lipid bilayer and are free to diffuse horizontally or vertically
in the plane of the lipid bilayer. This forms the so-called fluid
mosiac model of biological membrane. Since the membrane receptor
proteins are embedded in the lipid bilayer, it is reasonable to
expect that the chemical composition of the lipid bilayer may
impose certain constraints on receptor molecules which in turn
can affect their functional structure.
One of the approach in studying receptor-1ipid interaction
in cell membranes is by lipid modification. Membrane lipid
compositional changes can be achieved either in vivo, by dietary
means, or in vitro, by incubation of cells in media of restricted
lipid composition.
The study of membrane lipid modification on opiate receptor
function using a cell culture system has been only carried out
in the past few years. Our interest in this area is to determine
the extent in the lipid composition of the membrane can influence
opiate receptor activity. It was hoped that our results may
provide insights to the animals system.
Wilkening Nirenberg (1980) initially reported that the
presence of serum lipid is required for the morphine dependent
activation of adenyl cyclase in NG108-15 hybrids. This
requirement was further determined to be satisfied by linoleic
acid (C18:2). More recently, it has been reported that opiate
receptor as well as PG receptor binding are significantly reduced
when cells are grown in the presence of unsaturated fatty acids
(Ho Cox, 1982; McGee Kenimer, 1982). Changes in membrane
lipid composition after lipid exposure were actually observed
(McGee, 1981; Chan Fisherman, 1982). In our present study,
attempts were made to correlate the effect of membrane lipid
modification with the opiate receptor related activities. The
synthesis of opioid-like compounds after unsaturated fatty acids
exposure was also investigated. Our goal in this aspect of the
study is to find if there is any link between the lipid effect on
opioid binding and synthesis of opioid-like compounds.
III.2 Materials and Methods
A. Preparation methods
1. Preparation of delipidated calf serum
The delipidated calf serum (DLCS, Gibco) was prepared
according to the method of Cham Knowles (1976) as modified by
Wilkening Nirenberg (1980). Serum lipid was extracted with two
volumes of n-butanol:diisopropylether (40:60 vv) for 30-45 min.
and then centrifuged at 2,000 x g for 20 min. The organic phase
and interphase materials were discarded. The aqueous phase was
extracted with two volumes of diisopropylether. Ether was
separated by centrifugation and traces of ether remaining in the
calf serum were removed under a stream of nitrogen. The
extracted serum was extensively dialyzed against 20 volumes of
isotonic saline solution (132 mM NaCl, 0.8 mM CaCl, 0.8 mM
2
MgCl, 5 mM glucose, 0.8 mM NaH PO, 3.2 mM K HPO, pH 7.4) in a
2 2 4 2 4
cold room. The isotonic saline solution was changed 8 times at
12-h intervals. The serum was then aliquoted and stored at-
o
20 C until use.
2. Preparation of fatty acids supplemented culture medium
Arachidonic acid (C20:4), linolenic acid(C18:3), linoleic
acid (C18:2), oleic acid( C18:l), stearic acid (C:18) and
palmitic acid( C16) were obtained from Sigma, St. Louis, MO and
o
were stored at -20 C in ethanol under an atmosphere of nitrogen
at a concentration of 100 umolml. in the preparation of 100 uM
fatty acids supplemented culture medium, 100 ul of fatty acids
o
were injected into 5 ml pre-warmed (37 C) delipidated calf
serum(DLCS) and then sterilized by a Millipore filter and
adjusted to 100 ml with culture medium. Equal volume of ethanol






H-leucine was obtained from New England Nuclear (NEN) (60
2 3
Cimmol). To a 75-cm flask of cells in log-phase, 6 uCi of H-
leucine in phosphate buffer saline (PBS) was directly added to
the medium. After 6 hr of incubation, the cells were harvested
and washed extensely with PBS. Cells were then suspended in 1 ml
of PBS and 10 ml of 10% trichloroacetic acid (TCA) was added to
lyse the cells and to precipitate the proteins. The protein
precipitate was washed three times with TCA and the pellet
»
digested in 1 ml protosol. 0.5 ml of the digested protein was
counted by liquid scintillation spectrometry.
2. Determination of fatty acyl compostion of cell phospholipid
a. Total cell lipid extraction
43
Cells were harvested and washed three times with PBS and
lipid was extracted with 10 ml chloroform:methanol (3:2, v/v)
under an atmosphere of nitrogen in a cool room overnight.
Insoluble materials were pelleted by centrifugation and the
organic phase was removed. 3 ml of Sperry buffer (chloroform:
methanol 2 :1, v/v with 0.02% w/v CaCl) was added to extract
polar soluble protein. After then, the organic layer was blown
dry under a stream of nitrogen.
lb. Separation of phospholipids from the lipid extract
The lipid extract was resuspended in 50 ul chloroform and
phospholipids were separated by thin-layer chromatography (silica
gel G hexane:diethylether:acetic acid 60:40:1, v/v). The lipid
spot remaining at the origin (phospholipid spot) was scrapped out
and extracted by 5 ml of chloroform:methanol (1:1, v/v). The
organic phase was then dried under a stream of nitrogen.
c. Transmethylation of fatty acids from phospholipid
Transmethylation was carried out according to the procedure
of Ways et al. (1963). 1 ml of hexane:methanol:sulfuric acid
solution (0.5:2:0.04, v/v) was added to the phospholipid extract
for lnethylation reaction by heating the mixture at 60-70 C for
4 hr. After the samples were cooled, 5 ml 5% NaCl was added. The
esterified fatty acids were extracted two times by 5 ml hexane.
The hexane extract was then washed with 4 ml 2% KHCO3 and then
dehydrated by 1 g Na2SO4. The organic phase was filtered and
dried under nitrogen. The sample was redissolved in 100 ul
chloroform for gas-liquid chromatography.
d. Gas liquid chromatography (GLC) of esterified fatty acids
Fatty acids derived from phospholipids were separated by
gas-liquid chromatography using a column (18 inch x 6 feet)
packed with 10% SP2300 on Supelcoport (Supelco, Bellefonte, PA)
o
activated at 200 C. The elution profile was monitored by flame-
ionization (Model 3200 chromatrograph, Varian, Palo Alto, CA) and
the fatty acids was identified by comparision with known methyl-
ester standards (GLC20, Supleco).
III.3 Results and Discussions
A. Effects of fatty acids exposure on opiate receptor binding.
In agreement with previous report (Ho Cox, 1982), cells
3
grown in media containing different fatty acids bind H-DADLE
differently from the control cells. As shown in Fig. 3.1, the
3
amount on H-DADLE bound by the membrane homogenates of cells
grown in 100 uM saturated fatty acid, palmitic acid (C16) was
not significantly different from those of the control cells which
were grown in media supplemented with lipid-free serum (DLCS). In
contrast, cell grown in the presence of 100 uM unsaturated fatty
acids, oleic acid (C18:l), linoleic acid (C18:2), linolenic acid
(C18:3) and arachidonic acid (C20:4) show different degrees of
Fig. 3.1 Effects of exposure of NG108-15 cells to various fatty
3
acids on H-DADLE specific binding to cells membranes.
Cells were grown for 48 hr in the presence of 100 uM
3
fatty acids supplemented with 5% DLCS. Specific H-
DADLE (2 nM) binding to cell membranes was then
determined as described in Materials and Methods.
Results are presented as the% bound of the DLCS
control (240 fmolmg of protein). Binding were
performed in triplicates with standard deviations less
than 5%. C16 (palmitic acid), C18:l (oleic acid), C18:2






3H-UADLE blading reduction. The extent of the opioid binding
reduction seems to correlate with the degree of unsaturation of
fatty acids with the C20:4 being the most potent inhibitor in
opioid binding. In some conditions, cells exposed to C20:4 for
48 hr caused a reduction of opioid binding up to 80%.
The effect of unsaturated fatty acids on opioid binding
reduction can also been observed using intact cells instead of
cell membrane homogenates. Fig. 3.2 shows the result of a
representative experiment in which intact cell opioid receptor
binding was determined after exposure to unsaturated fatty acids
for 48 hr. The trend of inhibition is similiar to that in
membrane receptor binding. This unequivocally indicates that the
effects of unsaturated fatty acids is not due to actifacts
derived during the preparation of membrane homogenates.
We have preliminarily scanned a number of fatty acids and
observed that unsaturated fatty acids exposure can reduce opioid
binding significantly. In order to evaluate whether this
phenomenon is dose-dependent, cells were allowed to grow in the
presence of different concentration of unsaturated fatty acids.
As shown in Fig. 3.3 and Fig. 3.4, cells were exposed to
different concentration of C18:3 or C20:4 for 48 hr and then
observed the opioid binding acitivtiy. In both situtations, the
3
binding of H-DADLE were inhibited in a dose dependent manner.
The effect of unsaturated fatty acids on opioid binding
reduction follows a slow time course. As indicated in Fig. 3.5,
3Fig. 3.2 Effects of fatty acids on H-DADLE binding in intact
cells. Cells were grown in the presence of 100 uM fatty
3
acids for 48 hr. Intact cells H-DADLE (2 nM) binding
was then determined as described in Materials and
Methods. Results are presented as the% of specific
6
bound to lipid-free (DLCS) control (20 fmol 10
cells). Total binding were performed in triplicate with






33.3 Dose effects on H-DADLE binding of cells exposed to
linolenic acid (C18:3). Cells were grown in the
presence of various concentrations of C18:3 for 48 hr.
3
H-DADLE specific binding to cell membranes was then
determined.
C 1 8:3 conc6 ,uM
3. 3.4 Dose effects on H-DADLE binding in cells exposed to
arachidonic acid (C20:4)O Cells were grown in the
presence of various concentration of C20:4 (25-200 uM)
3
for 48 hr. The specific H-DADLE bound to cell
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fig. 3.5 Time course of linolenic acid (C18:3) exposure on
3
H-DADLE binding to ceil membranes. Cells were grown in
the presence of 100 uM C18:3 for the indicated time
3
periods. H-DADLE specific binding to cells membranes












when cells were exposed to 100 uM C18:3 for different periods of
time, the opioid binding acitivity did not reduce significantly
until cells were exposed for at least 48 hr. This observation
argues against any short term mechanism such as a detergent
effect of fatty acid on opioid binding. The long time course
required for inhibition suggests that unsaturated fatty acids are
required to be incorporated into the phospholipid of the membrane
before they can exert their effects on opioid binding.
In order to determine whether the reduction in binding is
due to a decrease in binding capacity or a decrease in binding
affinty, saturation binding at different ligand concentrations
3
were performed (Fig. 3.6 Fig. 3.7). Scatchard plots of H-DADLE
binding of cells grown in 100 uM C18:1 and C18:2 indicate that
the reduction of opioid binding is primarily due to a decrease of
binding capacity( Bmax) with little changes in binding affinity(
Kd). In the case of C18:3 and C20:4, similiar results were
obtained( Fig. 3.7) In aggreement with the previous experiments,
the potencies of inhibition is generally dependent on the degree
of unsaturation. Table 3.1 summaries the binding data after
unsaturated fatty acids treatments.
B. Reversibility of unsaturated fatty acids effects on opiate
receptor binding
So far, we have examined some of the inhibitory effects of
unsaturated fatty acids on opioid binding. In order to
3Fig. 3.6 Scatchard plots of H-DADLE binding in membranes of
grown in different fatty acids. Cells were grown in the
presence of 100 uM oleic acid (C18:1)( ); 100 uM
linoleic acid (C18:2) ( ) and lipid-free serum control
( ) for 48 hr. Saturation opioid bindings were assayed
as described in Materials & Methods. Points shown are
means of triplicate determinations with standard









3Fig. 3.7 Scatchard plots of H-DADLE binding in membranes of
cells grown in different fatty acids. Cells were grown
in 5% calf serum 5% delipidated calf serum (DLCS)
control 100 uM linoleinic acid (C18:3) and
100 uM arachidonic acid (C20:4) for 24 hr.
Saturation bindings to cell membranes were then assayed
as described in Material Methods. Points shown are
means of triplicated determinations with standard
deviations less than 5%.
3 H-DADLE SB, fmolmg
3Table 3.1 Summary of binding data on Scatchard analysis of H-
DADLE binding upon exposure of cells to unsaturated
fatty acids.





























Cells were grown in 5% calf serum (CS), 5% delipidated
calf serum (DLCS) and 100 uM fatty acids in 5% DLCS for
the indicated period of times. The data were obtained
from Scatchard plots by linear regression with r2 0.95.
investigate whether this effect is reversible, the following
experiment was performed. Cells were firstly grown in 100 uM
C20:4 for 48 hr and then transfered back either to normal, lipid-
free or C20:4 medium for different perioids of time. Binding with
H-DADLE was then carried out. As indicated in Fig. 3.8, cells
grew in C20:4 for 48 hr show a reduction of opioid binding by
about 80%. This reduction was reversible when the cells were
transfered back to normal or lipid-free media. The normal media
appears to be more effective and the binding was restored to
control level at about 48 hr. Cells exposed to lipid-free medium
could also reverse the inhibition effect of C20:4. However, in
this case, the time course is slower. In contrast, cells
continuously grew in C20:4 medium have opioid binding activity
about 50% of the control. When the cells that have opioid
binding being returned to the control level were re-exposed to
C20:4, it was found that the opioid binding was re-inhibited
again. Thus, effect of unsaturated fatty acid on opioid binding
is a reversible process and the time course in the recovery of
binding activity is relatively slow. Therefore, some mechanism of
synthesis such as protein synthesis, may be required for the
restoration opioid binding sites.
C. Effect of unsaturated fatty acids on protein synthesis
In previous experiments, it has been suggested that the
exposure to unsaturated fatty acids may reduce the number of
recfiptor protein and the reversal of receptor binding is achieved
Fig. 3.8 Reversibility of the inhibitory effect of arachidonic
3
acid (C20:4) on H-DADLE binding. Cells were first
grown in the presence of 100 uM C20:4 for 48 hr. Some
flasks of cells were then re-exposed to normal media
some flasks of cells were re-exposed to media in
5% lipid-free media( and some flasks of cells were
exposed to C20:4 for another 48 hr In cells re-
exposed to normal media for 48 hr, one flask of cells
was re-exposed to 100 uM C20:4 for 48 hr. At the
indicated time periods, cells were harvested and the
3
specific H-DADLE binding to cell membranes were then
determined. Results are presented as% of control. The
0 hr was the starting point for re-exposure after cell
have been exposed to C20:4 for 48 hr.
Incubation Time, hr
by the re-synthesis of receptor proteins. To further explore this
possibility, attempts to correlate protein synthesis with the
effects of unsaturated fatty acids on opioid binding was carried
out. Table 3.2 shows the effect of puromycin and cycloheximide
3
on the rate of H-leucine incorporation. Both puromycin and
cycloheximide were effective in reducing the rate of protein
synthesis at a drug concentration between 1 to 2 ugml. Opioid
binding of cells grown in the presence of puromycin was reduced
suggesting that protein synthesis is required for opiate receptor
molecules (Fig. 3.9). In order to ascertain the effect of
unsaturated fatty acids effects on protein synthesis, the rate
3
of H-lecucine incorporation by cells grown in unsaturated
fatty acids was determined. As indicated in Table 3.3, exposure
of cells to unsaturated fatty acids did not alter very much the
3
rate of H-leucine incorporation. If we assume the rate of
leucine incoporation is directly related to the activity of
protein synthesis, cells grown in unsaturated fatty acids had an
overall rate of protein synthesis very similar to those of the
control.
Even though the overall protein synthesis rate did not
change so much after unsaturated fatty acid treatment, there
still remains the possibility that specific synthesis of receptor
protein was retarded. To examine this, the effect of puromycin on
the reversibility of opioid binding after C18:3 treatment was
investigated. Cells were first exposed to C18:3 for .48 hr and
then transfered to either normal medium or normal medium
containing 1 ugml puromycin. As indicated in Fig. 3.10, specific
Table 3.2 Effects of protein synthesis inhibitors on 3H-leucine
incorporation of cells.















Cells were grown in the presence of indicated protein
synthesis inhibitors for 6 hr in the presence 6 uCiml
3
H-leucine. Cells were then harvested and treated as
described in Materials Methods. Viabilities of cells
were about 755%
3Fig. 3.9 Effects of puromycin on specific H-DADLE binding to
cells membranes. Cells were grown in the presence of
either 1 ugml or 2 ugml of puromycin for
the indicated periods of time. Specific H-DADLE
binding to cell membranes was then determined as
described in Materials Methods. Points shown are
means of triplicate determinations with standard
deviations shown in the figure.
3
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Cells were exposed to 100 uM fatty acids for 48 hr. Six
3
nours before assay, 6 uCi of H-leucine was added to
each flask of cells. Tne amount of leucine incorporated
was determined as described in Materials Methods.
Fig.3.10 Effects of puromycin on the blockage of resumption of
opioid binding after C18:3 exposure. Cells were exposed
to 100 uM C18:3 for 48 hr, and then re-exposed to
normal media re-exposed to normal media but in
the presence of 1 ugml puromycin and to C18:3 for
a further 48 hr Cells were harvested in the
3
indicated time periods and specific H-DADLE binding
to cell membranes was then determined as described in
Materials Methods. The time point designated as 0 hr
is the starting point for re-exposure and the level of
specific binding is the specific binding after cell
being exposed to C18:3 for 48 hr.
Incubation timo, hr
opioid binding could be restored when cells were exposed to
normal medium. In contrast, in the presence of the protein
synthesis inhibitor, puromycin, opioid binding activtity could
not resume back to the normal level. In fact, the amount of
3
H-DADLE bound in these cells was similiar to those cells grown
in C18:3 for a further 48 hr. The present experiment demonstrates
that the resumption of opioid binding activity requires the
synthesis of the protein.
D. Unsaturated fatty acid exposure and down regulation of opiate
receptors.
In the previous chapter, the opiates effect on the loss of
receptor was investigated. In order to to examine whether the
negative effect of unsaturated fatty acids on opiate receptor
is similar to that of opiate down regulation, an experiment was
performed to determine if these two events can be summated.
Table 3.4 shows the result the experiment» Cells were first
exposed to 100 uM C18:3 for 24 hr. Just six hours before assay,
2.5 uM of EKC were added to the control and C18:3 treated cells.
3
H-DADLE binding was then determined in the extensively washed
membranes. As indicated in Table 3.4, the loss of receptor
binding induced by EKC and C18:3 can be summated.
The effect of unsaturated fatty acids cannot act on the
receptor sites directly since naloxone cannot antagonize the
inhibitory effect of C18:3. Support for this claim is shown in
3Table 3.4 Effects of C18:3 and EKC exposure on specific H-DADLE




2.5 uM EKC 81+4.9 54.9
C18:3 114.7+8.7 36.1
C18:3+ EKC 39.8+5.4 77.8
t= 4 nr
CI8:3 112.9+8.4 37.1
C18:3+ EKC 49.9+4.1 72.2
t= 2 hr
C18:3 104.6+ 6.8 41.7
C18:3+ EKC 25.4+ 2.4 85.9
Cells were grown in the presence of 100 uM C18:3 and
DECS control for 24 hr. Before the binding assay,
2.5 uM EKC were added to the flasks of cells at time
points as indicated. Opioid binding to cell membranes
were determined as described in Material and Methods.
Table 3.5. When cells were exposed to naloxone (20 uM), no
significant reduction in opioid binding was observed. Moreover,
naloxone cannot reverse the inhibitory effect of C18:3. Since
naloxone is known to antagonize the inhibitory effect of DADLE
(see page 34), it is reasonable to conclude that the effect of
C18:3 on opioid binding involved a different mechanism from that
of down regulation.
E. Unsaturated fatty acid exposure and membrane lipid modification
From the results of previous experiments, it is apparent
that the effect of unsaturated fatty acids on opioid receptor
loss requires the incorporation of the fatty acids into the
membrane phospholipid. It is thus reasonable to attempt to
correlate the membrane fatty acid compositional changes with the
loss of opiate binding. The fatty acyl composition of membrane
phospholipids was determined by the GLC separation of the
esterified fatty acids as described in Materials and Methods.
Fig. 3.11 shows a typical GLC chromatograph in the separation of
fatty acyl compostion. The retention times of the esterified
fatty acids were generally proportional to the chain length and
the degree of unsaturation. It was found that C16 and C18 were
the major saturated fatty acid and C18:l was the major
unsaturated acids. Some unknown peaks were also observed and
their compostions were also compared upon different unsaturated
fatty acids exposure. Table 3.6 shows the membrane fatty acyl
composition of cells after being exposed to different
unsaturated fatty acids for 48 hre Cells grown in normal calf
Table 3.5 Effect of linolenic acid (C18:3) exposure in the
3
presence of opiate antagonist on H-DADLE binding.
3



























Cells were exposed to 100 uM C18:3 and 20 uM naloxone
for the indicated periods of time. Cells were then
3
harvested and H-DADLE binding to cell membranes was
determined as described in Materials Methods. Data
are obtained from triplicate determinations and are
presented as mean_+ S.D..
Fig.3.11 Gas-liquid chromatograh in the separation of fatty acids
of membranes phospholipids.
Retention time, min.
Table 3.6 Effect of fatty acid exposure to cells on membrane
phospholipid acyl compositions.
phospholipid acyi composition(%)















































Cells were grown in the presence of 100 uM fatty acid for 48 hr.
Cells phospholipids were extracted and assayed as described in
Materials and Methods.
serum have little polyunsaturated fatty acyl groups. On the other
hand, cells grown in the presence of unsaturated fatty acids show
an increase in percentage of unsaturated fatty acids to saturated
fatty acids. Moreover, cells grown in the presence of C18:2 and
C18:3 show a significant decrease in percentage of raono-
unsaturated fatty acid C18:l. Since the control cells contain
little unsaturated fatty acids in the membrane phospholipid, the
increased percentage of unsaturated fatty acids in membrane
phospholipids of the unsaturated fatty acid treated cells may
reflect the incorporation of exogeneuous fatty acids into the
cell membranes. In this respect, it has been found that more than
70% of exogeneuos unsaturated fatty acids can be incorporated in
the cell membranes (McGee, 1981).
In order to correlate the dose effect of unsaturated fatty
acids on opioid binding to the dose-related changes in membrane
lipid composition. An experiment was done by exposing cells to
different concentration of C18:2 and then determining the
membrane fatty acids composition as well as the opioid binding
activity. As shown in Table 3.7, opioid binding to cell membrane
homogenates decreased with increasing concentration of C18:2. On
the other hand, the membrane C18:2 composition also increased
with increasing concentration of C18:2 exposure as judged by a
gradual increase in the percentage of C18:2 to total fatty acids
composition (Table 3.8). Since the membrane lipid composition
changes would inevitably affect the physical properties of the
membrane which may in turn impose different constraint on
3Taole 3.7 Dose effect of C18:2 on H-DADLE binding and% C18:2 in
membrane phospholipid.
3


















Cells were grown in the presence of various concentrations of
3
C18:2 for 48 hr. H-DADLE (2 nM) binding and% of phospholipid
acyl C18:2 were assayed simultanous 1y as described in Materials
Methods.
Table 3.8 Dose effect of C18:2 on membrane phospholipid acyl
composi11o n.
phospholipid acyl compositions(%)





































Cells were grown in the presence of various concentrations of
C13:2 for 48 nr. Lipids were then extracted and phospholipid
acyl compositions were assayed as described in Materials and
Methods.
membrane proteins, it is reasonable to suggest that it is the
structural changes of membrane lipid that affect opioid binding
activity.
It has long been known that the increase in unsaturated
fatty acyl to saturated acyl composition in membrane phospholipid
leads to the increase in membrane fluidity (Gilmore et al.,
1979). A Change in membrane fluidity is known to affect the
interaction of membrane receptors with their ligands as well as
other cellular functions such as the length of the cell cycles
(De Laat et al., 1977). The reduction of opioid binding by
treatment with unsaturated fatty acid may be in part accountable
by an increase in membrane fluidity, which in turn induces a
translocation of the receptors and made them inaccessible to the
1igands.
F. Unsaturated fatty acids exposure and the opioid-like
compounds synthesis of the hybrid cells.
The fact that the hybrid cells can synthesize opioid-like
compounds prompt us to examine if these endogeneous ligands are
involved in the expression of receptor activity. In order to
investigate this possibility, the effect of unsaturated fatty
acids on the synthesis of opioid-like compounds in the hybrid
cells was determined. As shown in Fig. 3.12, the presence of
opioid-like compounds in cells exposed to C18:3 was not
significantly different from those of the control cells. (about
125
Fig. 3.12 Inhibition of the binding of I-B-endorohin to an
antiserum (RB 100) by B-endorphin and the cells
extracts. are those cells grew in DLCS control
while i are those cells grew in C18:3 for 48 nr. The
dilution of antiserum was 1:12,000. BBo was defined as
the percentage of specific radioactivity bound to the
antiserum in the presence of sample to the specific
radloacitlvity bound in the absence of any opioid
compounds. The total specific radioactivity bound was
2
5,700 cpm. The cell extracts from 3 x 150 cm flasks of
cells were dissolved in 400 ul RIA buffer, samples were
assayed in two fold dilutions to a final ratio of 1:16.
Points shown are means of duplicate determinations.
Cone, of B-«ndorphln y ngtub
63.8 fmo 1 ir-B-endorphin per 10 cells). Thus, as far as the
unsaturated fatty acid effect is concerned, opioid binding
reduction is unlikely to be linked with a reduction in the level
of opioid-like compounds.
CHAPTER IV
EFFECTS OF UNSATURATED FATTY ACIDS EXPOSURE ON
OTHER MEMBRANE RECEPTOR AND MEMBRANE-RELATED FUNCTIONS
IV.1 Introduction
In previous chapters, some characteristics of the effect of
unsaturated fatty acids on opioid binding to NG108-15 hybrids
were investigated. However, it is still not certain whether the
effect of unsaturated fatty acids exposure is specific for opiate
receptors or not. In an attempt to examine this, experiments were
carried out to determine the effect of unsaturated fatty acids on
other membrane receptors as well as membrane-related functions.
The aim of this parallel study is to try to determine whether the
inhibitory effect of unsaturated fatty acid is limited only to
the opiate receptors.
Since the a-adrenergic receptors in the NG108-15 cells have
been well characterized by Kahn e_t a_l. (1982), they were chosen
for comparision with the opiate receptors. The a-adrenergic
receptors of the hybrid cells, like the opiate receptors, are
functionally coupled to the adenyl cyclase in a GTP-dependent
3 3
inhibitory manner. Binding studies using H—WB—4101, H-prazocin,
3 3 3
H-para-aminoclonidine (PAC), H-epinephrine (EP) and H-
yohimbine (YOH) as labelling ligands indicate that the cells
possess primarily a adrenergic receptor subtype. In our studies,
2
3H-PAC, an a receptor agonist, was used as the ligand to study
2
the effect of unsaturated fatty acid s on adrenergic binding.
In addition to the a adrenergic receptors, the effect of
2++
unsaturated fatty acids on the membrane enzyme, Na K-
adenosine triphosphatase (ATPase) was also investigated.
+ +
Na K -ATPase is known to play an important role in the
transport of sodium and potassium across the membranes of cells.
The effect of unsaturated fatty acids exposure on cation
transport properties of a mouse neuroblastoma cells, Neuro-2A,
has been studied and it was found that oleic acid (C18:l) or
linoleic acid (C18:2) exposure for 1.5 hr did not significantly
+ +
alter Na K -ATPase activity even though active depolarization
of membrane potential was observed (Boonstra e_t al_., 1982). In
view of the close neuronal properties between NG108-15 and Neuro-
+ +
2A cells line, the Na K -ATPase activity of the hybrid cells
was also investigatled.
Experiments were also carried out in an attempt to
characterize and compare the membrane degradative enzymes for
enkephalin when cells were cultured in unsaturated fatty acids.
Enkephalins are known to be easily degraded in rat brain membrane
by aminopeptidase or specific enkepha1inase. In view of the
possibilty that the degradative enzymes for enkephalin may be
functionally coupled with receptor binding activity, we are
interested to determine how unsaturated fatty acid treatment may
influence the degradative rate of ligands for the opiate
r eceotors.
In addition to the above mentioned parallel studies, the
membrane glucose uptake activtiy of cells after being exposed to
unsaturated fatty acids was also examined.
IV.2 Materials and Methods
A. Assay of Na K -ATPase activities of NG108-15 cell membranes
Cells were harvested and the membrane particulate fraction
was prepared as described except tnat the membranes were washed
with 50 mM imidazo1e-HCl buffer (pH 7.0) and finally suspended in
the same buffer at a protein concentration of 150-250 ug ml.
Na K -ATPase activity was defined as the ATPase activity that
is ouabaln-sens111ve. For the total ATPase activity
determination, the assay mixture, done in triplicate, contained
400 ul cell membrane and 350 ul assay buffer (180 mM NaCl, 40 mM
KC1, 6mM MgCl, in imidazole buffer). For ouabaln-insensitive
2
ATPase activity determination, 0.4 mM ouabain was included in the
o
assay mixture. Samples were pre-incubated at 37 C for 10 min to
remove endogeneous ATP. Afterwards, 50 ul 48 mM ATP in assay
buffer was added to give a final concentration of 3 mM. Samples
o
were furtner incubated at 37 C for 30 min. The reaction was
terminated by adding 0.4 ml ice-cold HC10 (1.2 M) and samples
4
were immersed in ice—bath. Blank was prepared by addition of
HC10 to sample before addition of ATP. The samples were
4
centrifuged at 1,000 x g for 10 min. Inorganic phosphates
released from the assay mixtures were detected by taking 1 ml
a 1iquo ts of the protein-free supernatant into tubes containing
1 ml freshly prepared solution of 144 mM ferrous sulfate, 8.15 mM
ammonium molybdate in 0.58 M sulfuric acid. After standing at
room temperature for 5 min, samples were read at O.D. 700 nm
against a buffer blank. K HPO in the range of 0.03-0.5 umolml
was used as standard. Enzymatic activity was expressed in term
of pi released per mg protein per h. The Na K -ATPase
activity was calculated by substracting ouabain-insensitive
ATPase( Mg -ATPase) activity from the total ATPase activity.
B. Assay of enkephalin degradative enzyme activity in NG108-15 cells.
1. Assay procedure
Cell membrane particulate was prepared as described except
that the membrane was finally suspended in 30 mM Tris-HCl
(pH 7.4) at a concentration of about 1.5 mgml. Met-enkephain was
used as the substrate. Various amount of met-enkepha1in (5-30 ug)
were added to Ependorf microfuge tubes plus 5 ul H-met-
enkephalin (50 Cimmol, NEN; 4 uCiml). The mixtures were then
blown dry under a stream of nitrogen. 150 ul of cell membrane
suspension, preincubated at 37 C for 10 min, was added to each
tube and incubated further at 37 C. At various time periods (0-
30 min), 20 ul of 10% trichloroacetic acid (TCA) was added to
stop the reaction. Afterwards, the mixture was centrifuged to
separate out the membrane proteins. 50 ul of supernates were then
3
removed and analyzed for degradative products of H-met-
enkephalin by High Performance Liquid Chromatography (HPLC).
2. High Performance Liquid Chromatography (HPLC)
The degradation products of met-enkephalin were separated by
HPLC (Waters chromatograph) using a C18-reverse-phase Vydac
column. Samples were eluted with 32% methanol:0.02% triflouro-
acetic acid (TFA) at a flow rate of 1.0 mlmin. The elution
peaks were monitored by absorbance at O.D. 254 nM. Under this
conditon, the retention time is about 12 min for met-enlepha1in
and 3 min for tyrosine (Fig. 4.3). The amount of radioactive met-
enkephalin present in the sample was monitored collecting 1 ml
fractions and counting their radioactivity.
C. Assay of total glucose uptake
The glucose uptake was performed as modified from Kaminskas
(1979). Hybrid cells were freshly harvested and washed three
times with phosphate buffer saline (PBS, 0.01 M phosphate buffer,
pH 7.4, 0.15 M NaCl). Cells were finally suspended in PBS at a
6
concentration of 3 x 10 cellsml. 1 ml aliquot of cells
o
suspension was incubated at 37 C for 10 min. After then, 1 ml of
3
2mM H-Deoxy-g1ucose (NEN, 2 uCimmol) was added and mixed
gently. At different time durations up to 180 sec., 200 ul of
samples were removed and transfered into a tube containing 1 ml
ice-chilled 20 miM deoxy-glucose in PBS. This step was required to
inhibit further uptake of the tritiated ligand. To determine the
3
zero time and trapped radioactivity, 0.1 ml of ice-chilled H-
Deoxy-glucose was added into 0.1 ml cell suspension and kept in
ice-bath. The mixture was then transfered to 1 ml ice-chilled 20
3
mM deoxy-g1ucose and processed. After the uptake of H-Deoxy-
glucose has been quenched, samples were washed twice in cold PBS.
The cell pellet thus obtained was then digested in 1 ml 0.1%
Triton X-100. The radioactivity associated with the sample was
determined by liquid scintillation counting.
IV.3 Results and Discussions
A. Effect of unsaturated fatty acid on adrenergic receptor
binding of NG103-15 hybrid cells
Cells were exposed to different unsaturated fatty acids and
3
their adrenergic binding, using H-PAC as radioligand, was
determined. Fig. 4.1 shows the results of a representative
experiment. In contrast to the opiate receptors, a-adrenergic
receptor binding actually increased in cells exposed to
unsaturated fatty acids. The magnituude of increase was 18% for
linoleic aicd, 35% for linolenic acid and 35% for arachidonic
acid.
Fig. 4.2 shows the concommitant assay of adrenergic receptor
binding and opioid receptor binding using the same batch of cells
in a single experiment. In agreement with the previous results,
3
H-DADLE binding was suppressed when cells were grown in the
presence of unsaturated fatty acids. In contrast, similar
3
treatment produced an increase in H-PAC binding. Accordingly,
these results suggest that unsaturated fatty acids treatment can
Fig. 4.1 Effects of exposure of cells to various fatty acids on
3
H-PAC specific binding. Cells were grown in the
presence of 100 uM fatty acid for 48 hr. They were then
harvested and intact cells were used for binding as
described in Materials Methods. Results are presented















DLCS C18:1 C18:2 C18:3 C20:4
Fig. 4.2 Effects of exposure of cells to unsaturated fatty acids
on specific H-DADLE and H-PAC binding to cell
membranes. Cells were grown in the presence of 100 uM
fatty acid for 48 hr. From a single batch of cells, the
H-DADLE and l-i-PAC specific binding to membranes were
determined as described. Results shown are means of
triplicate determinations and are presented as% of
control level( 276 fmol/mg for H-DADLE binding and 29


















produce opposite effects in different receptor systems.
B. Effects of unsaturated fatty acids on Na+/ K+ -ATPase activity
Table 4.1 shows the effect of unsaturated fatty acid
+ +
treatment on Na/ K -ATPase activity. Using the cardiac
glycoside, ouabain++
(0.4 mM), as an inhibitor of the Na/ K-
ATPase, the activity of the enzyme was determined as the
difference between total and ouabain-insensitive activities. Our
results (Table 4.1) indicate that in cells grown in normal calf
+ +
serum, the ratio of ouabain-sensitive (Na/ K -ATPase) to
ouabin-insensitive activity was about 1:7, i.e., 1.44
umol Pi /mg.hr vs. 9.9 umol Pi/mg.hr. Upon exposure to oleic and
linoliec acid, a significant reduction in ouabain-insensitive
ATPase activities was observed. In contrast, no significant
change in ouabain-insensitive ATPase activtiy could be observed
when linolenic acid (18:3) was used. On the other hand, no
+ +
significant effects on Na/ K -ATPase activities was found when
cells were exposed to C18:1. C18:2 and C18:3.
Table 4.2 shows the results of an experiment when cells
treated with unsaturated fatty acids were simultaneously assayed
3++
for H-DADLE binding and Na/ K -ATPase activities. As
indicated, the opioid binding was significantly suppressed while
+ +
the Na/ K -ATPase activities remain essentially unchanged.
The fact that Na/ K -ATPase is unaffected by unsaturated
Table 4.1 Effect of unsaturated fatty acid on ATPase activities
of NG108-15 hybrid cells.
ATPase acitivities (umol Pi/mg.hr)
Total ouabain-insensitive ouabain-sensitive
DLCS 11.57+.08 9.6+.07 1.46+.1o
cs 11.3+.12 9.87+.1 1.44+.49
C18: 1 7.15+.16 5.93+.09 1.22+.19
C18:2 7.42+.10 6.35+.14 1.06+.17
C18:3 12.26+.2 10.85+.06 1.48+.21
2+
ouaba i n-insensitive ATPase= (Mg) -ATPase
+ +
ouabain-sensitive ATPase= (Na/ K )-ATPase
Cells were grown in media containing 5% DLCS, 5% CS or 100 um
unsaturated fatty acid in 5% DLCS for 48 hr. Cells were then
harvested for ATPase assay as described in Materials and Methods.
able 4.2 Effects of unsaturated fatty acids exposure to cells on
specific 3H-DADLE and Na+/ K+-ATPase activities.
3
H-DADLE SB Na/ K -ATPase Act.
( fmol/Mg) ( umol Pi/mg.hr)
DLCS 139.4+ 24 1.65+ .07
C18: 1 74.8+ 2.1 1.29+ .09
C18:2 67.0+ 10 1.60+ .07
Cells were grown in the presence of 100 uM C18:1 and 100
uM C18:2 for 48 hr. Cell membranes were prepared and the
opioid binding and ATPase acitivities were determined
simultaneously from the same batch of cells.
61
fatty acids exposure provides further evidence to show that the
effect of unsaturated fatty acid on opioid binding reduction is
rather specific.
C. Effect of unsaturated fatty acid on membranes enkephalin-
degradative enzyme activities of NG108-15 cells
Enkephalins are known to be degraded very rapidly in various
tissues, occurring primarily by cleavage of the Try-Gly bond. The
action of this rapid enkephalin degradation involves a spectrum
of peptidases with low specificies. These enzymes include:
puromycin-sensitive aminopeptidase (Barclay & Phillips, 1978)
enkephalinase, a carboxydipeptidase which cleaves enkephalins at
Gly-Phe peptide bond to form Try-Gly-Gly and Phe-Leu or Phe-Met
angiotensin converting enzyme which also cleaves the Gly-Phe
peptide bond enkephalinase B, an endopeptidase which cleaves
the enkephalin at the Gly-Gly peptide bond.
Rapid enkephalin degradating activity has also been
detected in a neuroblastoma cell line N4TG1, however, little is
known about the characteristics of enkephalin-degradative enzyme
activity of the hybrid cells NG108-15. Experiments were thus
carried out in an attempt to characterize and correlate opiate
receptor and enkephalin-degradation activities under the effects
of unsaturated fatty acids.
1. Characteristics of enkephalin-degradating enzymes activities
of NG108-15 cells
62
Since we are interested in the membrane bound enkephalin-
degradating enzymes, cell membranes were prepared for the assays.
Met-enkephalin was used as the substrate and the degraded
products were separated and monitored by High Performance Liquid
Chromatography (HPLC). In order to increase the sensitivity of
3
the assay, H-met-enkephalin (50 Ci/mmol, Amersham) was included
as a tracer by monitoring radioactivity changes. The purities of
3
met-enkephalin and H-met-enkephalin have been checked by HPLC
(Fig. 4. 3). A single peak was observed with the retention time of
3
12 min. The purity and recovery of H-met-enkephalin was found to
be greater than 95%.
3
In the determination of degradation products of H-met-
enkephalin, it was found that, by monitoring the radioactivity
profile of samples, the majority of the degradated products was
3
due to the formation of degraded H-tyrosine which is eluted
without aborption onto the column. Monitoring the enzyme actvity
can thus be achieved by determining the appearance of tyrosine
or disappearance of met-enkephalin radioactivity.
Fig. 4.4 shows a typical HPLC elution profile of time-
dependent degradation of met-enkephalin by cell membrane
degradating enzymes. At least two degradative products can be
separated. Fig. 4.5 shows the rates of met-enkephalin degradation
as a function of substrate concentrations (29 uM to 174 utl). As
shown in the figure, the rate of enkephalin degradation follows
.ig. 4.3 High performance liquid chromatography (HPLC) elution
3
profile of met-enkephalin and H-met-enkephalin. Five
ul of sample (1 mg/ml) were eluted isocratically from a
C18-reverse phase Vydac colummn with 32% methanol in
0.02% triflouroacetic acid. The flow rate was 1 ml/ruin.
Peaks were monitored by absorbance at O.D. 254 nm. The
shaded area represented the amount of radioactivity of
3
H-met-enkephalin being eluted The recovery of
materials applied was higher than 90%.
Time, min
Fig. 4.4 High performance liquid chromatographs of degradative
products of met-enkephal i n. 10 ug of met-enkephlin was
incubated with NG108-15 membranes for 15 min and the
enzymatic dagradative products of met- enkephalin were
separated by a C18 reverse phase Vydac column with 32%
methanol in 0.02% TFA. The flow rate was 1 ml/min.
Fig A shows the HPLC elution profile of sample at t= 0
min Fiy. B shows the HPLC eluiton profile of sample at
t= 15 min. Arrows show the degradative products of
met- enk ephalin.
A Met- EN K




Q 4 8 1 2 16
Retention Time, min.
Fig. 4.5 Rate of met- enkephalin degradation by membrane
degradative enzymes as ..a function of substrate
concentration. The degradative enzymes assay was
performed as described in Material & Methods. Cell
membranes protein of the assay was about 170 ug. 3 H-
.met-enkephalin used per assay tube was about 18,000
cpm. The rate of degradation was monitored by the rate
3














approximate Michalis-Mentan kinetics over the whole substrate
concentration range studied. Linewear-Burk plot of the result
shows a linear relation with the Km value of about 0.2 mM and
Vmax about 410 nmol met-enkephalin degraded per hr per mg of
protein (Fig. 4.6).
It has been observed that bacitracin and puromycin inhibit
the degradation of enkephalin by brain membrane preparations
(Miller et al., 1977) as well as intact neuroblastoma cells
(Hazum et al., 1979). Similar inhibitory properties were found
with NG108-15 cell membrane preparations. As shown in Fig. 4.7
and Fig. 4.8, the half-maximum inhibition of the degradative
enzymes activities were about 800 uM for bacitracin and 200 um
for puromycin. The puromycin inhibitory effects, as compared to
that using intact neuroblastoma N4TG1 cells (Hazum et al., 1979),
was relatively less potent. This indicates that the peptidases in
NG108-15 cells were probably the puromycin-resistant type.
2. Effects of unsaturated fatty acids on enkephalin-degradating
enzymes activities of NG108-15 cells.
In order to determine whether opioid binding reduction can
be correlated with changes in enkephalin-degradating mechanism,
the enkephalin-degradating enzymes activities of cells grown in
the presence of C18:3 and C20:4 were compared with those grown in
lipid-free control. As shown in Fig. 4.9, the rates of
degradation of met-enkephalin at various substrate concentrations
were essentially identical among the unsaturated fatty acid
Fig. 4.6 Lineweaver-Burk plot for met-enkephalin degradative
enzymes activities of NG108-15 cell membranes. S= met-
enkephalin concentration V= rate of met-enkephalin
peak disppearance. From the calculation, the Km and











Fig. 4.7 Dose effect of bacitracin inhibition on cell
membranes enkephalin-degradative enzymes activities
























Fig o 4.9 Rate of met-enkephalin degradation
by membrane-bound
degradative enzymes of NG108-15 cells as
a function of
substrate concentration. Cells were grown in media
containing 506 DLCS( ), 100 uM C18 :3 (▲) and 100 uM
020:4() for 48 hr. Cells were then harvested and the
cell membranes were prepared for the assay. The














treated and control cells. Linweaver-Burk plots of the assays
show linear relations without significant alteration in Vmax and
Km values (Fig. 4.10). Thus, the present result do not support
the view that the degradative enzymes for met-enkephalin could be
affected by unsaturated fatty acid treatment. Since the hybrid
cells possess a large number of opiate receptors, the high
activities in enkephalin-degradation enzymes may be of importance
in regulation of receptor functions. In the present studies, it
is concluded that the enkephalin-degradation activity is probably
unrelated to the opiate receptor number. In other words, the
regulation of receptor and the degrada t i ng activitiy of the
ligands may be controlled under different mechanisms. The result
also demonstrated that unsaturated fatty acids did not generally
inhibit membrane proteins synthesis or activities.
D. Effects of fatty acids exposure on glucose uptake
In the previous studies, some of the membrane enzymes and
membranes receptor protein have been investigated when cells were
exposed to unsaturated fatty acids. The results suggested that
unsaturated fatty acids treatment cannot inhibit membrane protein
turnover in a similar manner. In this section, the glucose uptake
properties of cells grown in different fatty acids was also
examined. The glucose uptake rate and the total glucose uptake of
cells can reflect their metabolic activities. The uptake of
glucose was believed to be promoted by an active transport
mechanism namely, by the membrane bound glucose transporter
Fig. 4.10 Lineweaver-Burk plots for net-enkephalin degradative
enzymes activities of NG108-15 cell membranes. Cells
were grown in media containing 5% DLCS(), 100 um
C18:3 (▲) and C20:4 (■) for 48 hr. S= met-enkephalin
concentration V= rate of met- enkephalin degradation.
1S x 103, (uM)1
(carrier). In the present studies, the total uptake of glucose
was examined. As shown in Fig. 4.11, the rate of glucose uptake
was a rapid process and total equilibration could be attained in
about 150 sec.. There was no significant difference in the
initial rate as well as total glucose uptake among the cells
exposed to 100 uM C18:l, 100 uM C18:2 or to DLCS. However, cells
grown in the presence of 100 uM C18 and 100 uM C20:4 show a
significant retardation of the intitial rate as well as the total
glucose uptake. The fact that glucose uptake process was not
affected by C18:l and C18:2 treatment suggests that the metabolic
rates of the treated cells were not severely inhibited. Since C18
exposure to cells have been known to a signigicant toxic effect
(McGee, 1981), the effect of C18 on the glucose uptake
retardation may be in part due to this toxicity. On the other
hand, the reason why C20:4 exposure leads to an inhibition of
glucose uptake remains uncertain.
The result that C18:l and C18:2 exposure to cells did not
show significant effect on glucose uptake provides further
evidence to indicate that C18:l and C18:2 did not alter the
metabolic process very much and that the reduction of opioid
binding was not due to a retardation of cell metabolism.
Fig. 4.11 Effect of fatty acids on glucose uptake. Cells were
grown in media containing 5% DLCS 100 uM C18
( O), 100 uM C18: 1( 100 uM C18: 2 and 100 uM
C20: 4 for 48 hr. Cells were then harvested and





Since membrane lipids are known to play a crucial part in
the properties of membrane receptor functions (Loh et al., 1980),
the study of lipid requirements for opiate receptors function is
thus of considerable interest. Early studies have suggested that
the opiate receptors consist of a protein and lipid moeity since
digestion with protease and phosphao1ipase A inactivate the
2
binding properties of these receptors. (Bidlack Abood, 1980;
Lee Smith, 1980). In view of this, the perturbation of
membrane lipid composition may provide insights to our
understanding of the molecular nature of the opiate receptors.
One approach in studying membrane 1ipid-protein (receptor)
interactions is by altering the membrane lipid composition either
by dietary means or by exposing cells to exogeneous fatty acid in
cell culture. In the present study, some of the opioid binding
characteristics of the neuroblastoma x glioma hybrid NG108-15
cells grown in media supplemented with unsaturated fatty acids
were investigated. The specificity of the effect of unsaturated
fatty acids treatment on opioid receptor was also examined by
parellel studies with other membrane receptors or proteins. Our
data suggest that unsaturated fatty acids treatment acts
specifically to inhibit opioid binding.
Similar studies on the effects of unsaturated fatty acids to
membrane receptors binding properties of the hybrids have
recently been reported by other group (McGee Kenimer, 1982). It
was found when hybrid cells were exposed to arachidonic acid
(C20:4), linoleic acid (C18:2) and oleic acid (C18:1) a reduction
3
in H-etorphine binding was observed. This result is consistant
3
with what we have found using H-DADLE as the opiate receptor
binding 1igand.
The results of our study demonstrate that the effects of
unsaturated fatty acids on opioid binding reduction can be
observed in both the intact cells and membrane preparation. The
degree of reduction in binding appears to correlate with the
degree of unsaturation of the fatty acids. Arachidonic acid
(C2:4), which has four double bonds, is the most potent
inhibitor. Since the majorty of the exogeneous fatty acids can
be metebolized by the cells and eventually get incorporated into
the membrane phospholipid (Yavin et al., 1975), the correlation
may reflect the influence of different unsaturated acyl groups in
the membrane phospholipid. Nevertheless, it is prematured to
conclude' that the degree of membrane unsaturation is directly
n r r i- i v n o f- i Ann
The decrease in opioid binding was found to be time-
dependent and is a relatively slow process. The effect of
unsaturated fatty acids on opioid binding reduction was not
significant until after at least 36-48 hrs of incubation with
lUt) uM of unsaturated fatty acid. This phenomenon was slightly
different from the effects of unsaturated fatty acids on PG
receptor binding inhibition of the hyrid cells (McGee Kenimer,
1932). In this case the reduction occurs as early as 6 hr after
exposure to fatty acids. Based on the different time-course of
inhibitions, it appears that unsaturated fatty acids may affect
PG and opiate receptor binding in a different way. The slow time
course of the inhibition in the case of the opiate receptors
suggests that the effect of unsaturated fatty acid on opioid
binding is not a direct one. It is more likely that fatty acids
have to be incorporated into the membrane as phospholipids first
before they can exert their effects. Another piece of indirect
evidence supporting the view that the effect of unsaturated fatty
acids on opioid binding reduction does not involve the receptor
sites came from the experiment with naloxone. Even when the
receptors are protected by a high concentration of this opiate
antagonist, unsaturated fatty acids can still exert their effect
(Table 3.5).
Unsaturated fatty acids are metabolized and esterified by
the cells. More than 70% of the exogeneous unsaturated fatty
acids are incorporated into the phospholipid of the cell membrane
(Chan Fishman, 1932; McGee, 1981). As a result, the degree of
unsaturation in the membrane also increases. Our anslysis of the
acyl composition of the phospholipid extracted from the cells
after unsaturated fatty acids treatment is in line with this
(Table 3.6). Since an increase in membrane unsaturation is
associated with an increase in membrane fluidity (Gilmore et al.,
19 7 9), it is reasonable to speculate that it is the changes in
membrane fluidity that may affect the opioid binding activity.
In addition to an increase in membrane unsaturation,
unsaturated fatty acids exposure also causes an increase in total
amount of phospholipid which in turn decreases the membrane
choles trol to phosphoplipid ratio. Moreover, the amount of
phosphatidylenthanolamine in the membrane is increased by as
much as 60% at the expense of phosphatidylinosito 1 and
phosphatidylcholine (McGee, 1981). In this respect, since part of
the opiate receptor is made up of lipid, changes in phospholipid
composition may cause a structural changes of the opiate
receptors.
Unsaturated fatty acids exposure to cells on opioid binding
reduction was primarily due to the loss of total number of
receptor (Bmax) with little change in apparant dissociation
constant (Kd). This suggests that the molecular integrity of the
opiate receptors in unsaturated fatty acid-treated cells is not
significantly altered. It appears that unsaturated fatty acids do
not act as a detergent in reducing opioid binding. If this is the
case, the binding affintiy should have been affected.
The effect of unsaturated fatty acids on opioid binding
reduction is a reversible process (Fig. 3.8). The unsaturated
fatty acid-treated cells can resume opioid binding simply by re-
exposure to normal medium. The time-course of the resumption of
opiate binding is also a slow process. It requires at least 48 hr
for a complete resumption of opioid binding to the control level.
In addition, when the cells are re-exposed to media containing
unsaturated fatty acid, inhibition of opioid binding remains
effective. However, it appears that the re-inibition of opioid
binding follows an even slower time-course. Based on the time
course of inhibition and reactivation. the of nn-ieo
receptors is unlikly due to a masking effect or the conversion
of the receptor to an inactive form. It appears that the number
of opiate receptors has actually decreased and the resumption of
opiate receptors requires time for re-synthesis. The finding
that protein synthesis inhibitor puromycin can prevent the
resumption of the opiate receptors of cells after unsaturated
fatty acid exposure supports this line of reasoning (Fig. 3.10).
An alternate explanation to account for the opiate binding
loss may be due to either an impaired insertion of opiate
receptors into the membrane after fatty acid treatment or an
increase rate of removal of opiate receptors from the cell
A third mechanism that may account for the effect of
unsaturated fatty acids is the way this treatment can influence
the length of the cell cycle. The insertion of membrane
componants during the cell cycle is believed to be phase-specific
(De Laat et al., 1981). It has recently been reported that
expression of opiate receptors in the neuroblastoma x glioma
NG108-15 cells is also cell-cycle dependent (Scheideler et al.,
3
1933). Specific H-DADLE binding to cell suspension is maximal at
the S and G2 phase. In this respect, it is possible that exposure
to unsaturated fatty acid may arrest the cells at certian phase
of the cell cycle, presumably M and G1 phase. Since there is a
decrease in the percentage of cells in the S and G2 phase, this
may lead to a reduction in the overall opioid binding of the
cell populations. Whether this is the case remains to be
es tablished.
It is important to note that the loss of opiate receptors in
unsaturated fatty acid-treated cells is not due to the toxic
action of the fatty acids. Unsaturated fatty acid exposure did
not cause observable toxic effect to the cells. In contrast, it
has been reported that unsaturated fatty acids can promote cell
growth (McGee, 1981) and antagonize the toxic effect of saturated
fatty acids (Doi et al., 1978). In support of this claim, the
morphology of cells grown in media containing unsaturated fatty
acids did not alter very much and the rate of protein synthesis,
3
as judged by the rate of H-leucine incoporation, was not
significantly retarded.
The loss of opiate receptors by treatment of unsaturated
fatty acids cannot be regarded as an universal phenonmenon.
Parellal studies on adrenergic receptors demonstrated that
unsaturated fatty acids affect adrenergic receptor binding quite
differently from that of opiate binding. It was found that
unsaturated fatty acid exposure to cells causes an increase in
adrenergic binding by as much as 50% in both intact cells and
cell membrane preparations. It has not yet been determined
whether the increase is due to an increase in total number of
receptor or an increase in binding affinity. However, the data at
least show that changes in the membrane lipid composition do not
cause nondiscriminate reduction in membrane receptor binding. In
support of this, it was found that alteration of membrane lipid
unsaturation leads to an increase in insulin receptor number but
a decrease in receptor affinity in Friend erythroleukemia cells
(Ginsberg et aL., 1981). Similiar studies on the effect of
membrane modification in Ehrlich ascite tumor cells also
demonstrated that an increase in unsaturation of plasma membrane
phospholipid was associated with an increase in insulin receptor
number but a decrease in binding affinity (Ginsberg et al.,
1982). These results again reinforce the idea that a change in
membrane lipid composition may not lead to a general reduction in
receptor protein.
Studies on the effect of unsaturated fatty acids exposure to
+ +
neuroblastoma x glioma cells on Na K -ATPase activity are also
of great interest. The enzyme plays an important role in the
+ +
transportation of Na and K across the membrane which in turn is
responsible for maintaining membrane potential. Our results
2+
indicate that although the Mg -ATPase (ouabain insensitive
ATPase) activity is significantly inhibited in unsaturated fatty
+ +
acid--trea ted cells, the Na K -ATPase activity is not
significantly affected. Similiar studies on the role of membrane
+ +
lipids in the modulation of membrane Na K -ATPase has been
extensively investigated in mouse neuroblastoma cells N18TG2, C6-
glioma cells (Chan Fishman, 1982) and neuroblastoma cells
Neuro-2A (Boonstra et al,, 1982). Exposure to arachichondic acid
+ +
inactivate Na K —ATPase activity in C6—glioma cells but have
litte effect on N18TC2 cells. On the other hand, supplementation
of oleic acid or linoleic acid to Neuro-2A cells has no
+ +
significant effect on Na K -ATPase activity. In view of these
+ +
findings, it appears that the lipid requirement on Na K-
ATPase activity may be different between different cell types.
In the study of enkephalin-degradating enzyme activity, the
initial aim is to find if there is any correlation between
enkephalin degradation and the receptor loss after unsaturated
fatty acids treatment. Since it is known that the hybrid cells
can synthesize opioid like compounds (Glaser e_t a_l., 1980, 1982)
(Fig. 1.13), it is of interest to determine whether the receptor
loss is associated with any changes in enkephalin degrading
activity. Our data indicate that neuroblastoma x glioma cells can
effectively degrade enkephalins by the membrane-bound enzyme(s).
These enzyme(s) can be inhibited by puromycin and bactracin. The
main cleavage of enkephalin is at the Try-Gly amide bond.
According to our results, exposure of cells to unsaturated fatty
acids did not alter the enkepha1in-degradating enzyme activity.
This suggests that the degradation of enkephalin is not
associated with the reduction in opiate receptor number. In line
with this, Hazum e_t a_l. (1979) found that the enkephalin-
degradating enzymes activity of N4TG1 cells, which also bear
opiate receptors, remained unaffected even though the opiate
receptors are totally blocked by opiates agonists such as
morphine, leu-enkepha1in and DALDE.
Opiate receptors are found functionally coupled to adenly
cyclase in a inhibitory manner (Sharma et alM 1975). It is also
interesting to find whether unsaturated fatty acids exposure may
also affect the adenly cyclase activity of the cells. In this
respect, it was found that linoleic acid is required for the full
i n n f t-ho 1 nnn- 1 l uoH mnr nh i m rlmnnnrlnnf- i -i r-
adenly cyclase (Wilkening Nirenberg, 1980). On the other hanc
the adenyl cyclase activity of the hyrid cells remair
unaffected even there was a large change in phospholipid fatt
acid composition (McGee Kenimer, 1982). It appears that th
lipid requirement of receptor coupling and receptor expressio
may be different.
Although the exact mechanism of how unsaturated fatty acid,
can reduce opiate receptor binding is still unknown, the presen
study at least demonstrates that this effect is unlikely to be
general phenomemon. The most probable mechanisms may involv
receptor synthesis, receptor turnover or receptor expressioi
during cell cycle.
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